Browse Tag: Stock

TEVA Stock Price – News – Teva Pharmaceutical Industries Ltd, teva pharmaceuticals stock.#Teva #pharmaceuticals #stock

Teva Pharmaceutical Industries Ltd. ADR

Nov 30, 2017 4:02 p.m. ET EST

Loading more news…

There is no more news available.

  • Nov 29, 2017 New Migraine Drugs Show Promise in Race to Sell Next-Generation Treatments The Wall Street Journal
  • Nov 28, 2017 Teva shares surge on corporate shake-up MarketWatch.com
  • Nov 27, 2017 Teva’s New CEO Starts Turnaround Plan at Struggling Drugmaker The Wall Street Journal
  • Nov 27, 2017 Stocks to Watch: Amazon, Time, Alkermes, Biogen, SandRidge, Barracuda Networks WSJ Blogs
  • Nov 10, 2017 Why tax-bill fears may be one big contributing factor in junk bond slump MarketWatch.com
  • Nov 8, 2017 Teva’s stock and bonds walloped after Fitch downgrade to junk MarketWatch.com
  • Nov 7, 2017 Why Mallinckrodt’s Woes Matter to All Drug Makers The Wall Street Journal
  • Nov 7, 2017 Teva’s latest quarter was even worse than already-low expectations MarketWatch.com
  • Nov 6, 2017 A Rare Bright Spot for Mylan The Wall Street Journal
  • Nov 2, 2017 Teva’s Rebuild Is Going Nowhere The Wall Street Journal
  • Nov 2, 2017 Teva Cuts Outlook Again in Perfect Storm of Problems The Wall Street Journal
  • Nov 2, 2017 Teva earnings: Facing down cheaper generic prices, generic competition of its own and a lot of debt MarketWatch.com
  • Nov 1, 2017 Another Headache for Teva Shareholders WSJ Blogs
  • Oct 31, 2017 States Expand Price-Fixing Accusations Against Generic Drug Companies The Wall Street Journal
  • Oct 23, 2017 Allergan: That $15 Billion Sure Went Fast The Wall Street Journal
  • Oct 23, 2017 Dividend Fears Take Toll on GE Shares The Wall Street Journal
  • Oct 17, 2017 Impax Laboratories and Amneal Pharmaceuticals Agree to Merge The Wall Street Journal
  • Oct 16, 2017 Impax Laboratories and Amneal Pharmaceuticals Near Merger Agreement The Wall Street Journal
  • Oct 16, 2017 Allergan Loses Patent Fight in Federal Court The Wall Street Journal
  • Oct 16, 2017 Lost beneath headlines of five-figure drug costs — pharmaceutical price growth is weakening MarketWatch.com

Loading more news…

There is no more news available.

  • Nov 29, 2017 The New England Journal of Medicine Publishes Data from Pivotal Phase III Trial of Fremanezumab for the Preventive Treatment of Chronic Migraine PR Newswires
  • Nov 27, 2017 Teva Announces New Organization Structure and Leadership Changes PR Newswires
  • Nov 15, 2017 Teva Announces Prescription Copay Savings Program for Generic Gleevec(R) Tablets in the United States PR Newswires
  • Nov 2, 2017 Teva Announces Completion of Plan B One-Step(R) Divestiture to Foundation Consumer Healthcare PR Newswires
  • Nov 2, 2017 Teva Reports Third Quarter 2017 Financial Results PR Newswires
  • Nov 1, 2017 Teva Announces Completion of PARAGARD(R) Divestiture to CooperSurgical PR Newswires
  • Nov 1, 2017 FDA s Efforts to Accelerate New Drug Development is a Big Bonus for Biotech and Pharma Stocks PR Newswires
  • Oct 31, 2017 Teva Wins Generic Uceris(R) Patent Trial PR Newswires
  • Oct 30, 2017 Kåre Schultz to Join Teva as President and Chief Executive Officer on November 1, 2017 PR Newswires
  • Oct 26, 2017 Teva to Highlight Asthma Data at the 2017 American College of Allergy, Asthma and Immunology Annual Scientific Meeting PR Newswires
  • Oct 23, 2017 Glancy Prongay Murray Reminds Investors of the October 23rd Deadline in the Class Action Lawsuit Against Teva Pharmaceutical Industries Ltd. (TEVA) PR Newswires
  • Oct 19, 2017 Teva to Highlight New Data in Multiple Sclerosis at Joint ECTRIMS — ACTRIMS Congress in Paris PR Newswires
  • Oct 18, 2017 TEVA Reminder Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Teva Pharmaceutical Industries Ltd. PR Newswires
  • Oct 18, 2017 Clinical Trials and Advanced Development of Innovative Drug Treatments Boosting Biotech Sector Gains PR Newswires
  • Oct 17, 2017 Teva Announces Submission of Biologics License Application for Fremanezumab to the U.S. FDA PR Newswires
  • Oct 14, 2017 DEADLINE ALERT: Brower Piven Reminds Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Teva Pharmaceutical Industries Limited to Contact the Firm PR Newswires
  • Oct 11, 2017 INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Teva Pharmaceutical Industries Ltd. Investors and Encourages Investors to Contact the Firm (TEVA) PR Newswires
  • Oct 10, 2017 Teva to Report Third Quarter 2017 Financial Results on November 2, 2017 PR Newswires
  • Oct 6, 2017 TEVA PHARMACEUTICAL SHAREHOLDER ALERT: ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Teva Pharmaceutical Industries Limited – (TEVA) PR Newswires
  • Oct 5, 2017 Teva Announces tomy s Award Winner at Oncology Satellite Symposium During the 7(th) International Symposium on Acute Promyelocytic Leukemia (APL) in Rome, Italy PR Newswires

Loading more news…

There is no more news available.

Major Holders

Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source: FactSet Fundamentals

Feedback on our new quotes?EMAIL US

Key Stock Data

Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company, which provides patient-centric healthcare solutions.

Key Executives

Competitors (TEVA)

Real-time U.S. stock quotes reflect trades reported through Nasdaq only.

International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times.

Quote data, except U.S. stocks, provided by SIX Financial Information.

Data is provided as is for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

All of the mutual fund and ETF information contained in this display was supplied by Lipper, A Thomson Reuters Company, subject to the following: Copyright 2017 © Thomson Reuters. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Bond quotes are updated in real-time. Source: Tullett Prebon.

Currency quotes are updated in real-time. Source: Tullet Prebon.

Fundamental company data and analyst estimates provided by FactSet. Copyright 2017 FactSet Research Systems Inc. All rights reserved.





Teva stock plummets 18% after rough quarter in US generic drug market, teva pharmaceuticals stock.#Teva

Teva stock plummets 18% after rough quarter in US generic drug market

Teva pharmaceuticals stock

Shares of Teva Pharmaceutical fell more than 18 percent in morning trading Thursday after the company reported lower-than-expected second-quarter earnings.

div > div.group > p:first-child”>

Teva missed estimates for both earnings per share and revenue, and interim CEO Yitzhak Peterburg blamed the poor performance on a saturation of the U.S. generic drug market.

“[Teva] experienced … greater competition as a result of an increase in generic drug approvals by the U.S. FDA,” Peterburg said in the earnings release. He added that “customer consolidation” hurt sales in the U.S., before saying competition hurt new product launches, some of which were delayed in the recent quarter.

Earnings per share of $1.02 was 4 cents below what analysts surveyed by Reuters expected. Revenue also fell short of analyst forecasts by more than $300 million, coming in at $5.686 billion compared to the expected $5.718 billion.

Peterburg said instability in the Venezuelan bolivar had a material effect, reducing revenue by $183 million compared to the same quarter last year.

On June 28, Peterburg warned that the global health-care industry faces a “huge disruption,” saying at the World Economic Forum that he believes “it will affect” the pharmaceutical industry.

Teva Pharmaceutical, headquartered in Israel, calls itself the largest producer of generic medicines. In specialty medicines, Teva has treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system.

The pharmaceutical company lost its CEO on February 7 when Erez Vigodman resigned suddenly amid reports of a bribery investigation by the Israel Police. The biggest company in Israel, Teva allegedly paid bribes into the hundreds of millions of dollars and falsified documents in order to hide them.

Teva’s stock fell more than 14 percent in pre-market, before continuing to decline after the market open. Shares of the company were down nearly 14 percent this year ahead of Thursday’s open.

Teva pharmaceuticals stock





Megger Electrical Testers – Meters for Sale, Transcat, kv pharmaceutical stock.#Kv #pharmaceutical #stock

Megger Electrical Test Equipment

Do you have an electrical test or measurement challenge? Megger one of the industry s most recognizable brands has a full-service solution. The company has been a leading global provider of test equipment and measuring instruments for electrical power applications for over 100 years, and has been so influential in the creation and development of electrical insulation testers that the term Megger has become synonymous with these devices. The company is resolute in providing solutions that serve highly critical areas, such as: ground resistance and insulation testing, cable fault locating, and power quality testing.

Transcat is proud to be the industry s largest Megger distributor, with a unique suite of services to equip electricians, technicians and engineers with the world s foremost Megger instruments. In addition to hundreds of Megger instruments, we offer electrical calibration services and Megger instrument repair services as your full-service Megger solution.

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock





Arena Pharmaceuticals Announces Positive Phase 2 Results in PAH – arna, Seeking Alpha, arena pharmaceuticals

arena pharmaceuticals stock

Arena Pharmaceuticals Announces Positive Phase 2 Results in PAH

  • Ralinepag shows remarkable improvement in patients with pulmonary arterial hypertension.
  • Positive results in the PAH trial was a much needed change after the company’s first FDA approved product didn’t sell well.
  • Cash is only expected to last for the next 12 months.

Monday, Arena Pharmaceuticals (ARNA) announced positive phase 2 results in patients with pulmonary arterial hypertension. The stock shot up as high as 41% in after-hours trade on the news to $25.99 per share. These results paint a new picture for Arena who has suffered over the last few years with an obesity drug known as Belviq.

The phase 2 trial recruited a total of 61 patients with pulmonary arterial hypertension — PAH. Patients in the study either took Ralinepag or a placebo. The trial met on the primary endpoint of the study in that the drug demonstrated a statistically significant absolute change in baseline in pulmonary vascular resistance — PVR. Patients treated with ralinepag showed a 29.8% improvement in PVR compared to placebo with a p-value of p=0.03. That means that the primary endpoint reached statistical significance. In addition, there was a 20.1% improvement in patients treated with ralinepag compared to baseline. Arena plans to present the full positive data at a future medical conference. What is even better is that this data gives the company the backing to move to a phase 3 clinical trial. The Chief Scientific Officer of Arena, Preston Klassen, M.D. had this to say in a quote:

“It is exciting to see the positive nonclinical pharmacological profile translating into potentially the first oral prostacyclin therapy that may approach consistent therapeutic levels without the complexity of parenteral (IV) therapy. These data give us confidence to move expeditiously toward a Phase 3 clinical program.”

What is being described above is that the oral drug from Arena Ralinepag might be close to achieving the same therapeutic effect as those drugs that are given intravenously. An oral treatment option for these patients would be a lot more ideal. PAH is a life threatening disease because there is a strain on a patient’s heart which can lead to heart failure. What happens in PAH is that there is an increase in pressure in the arteries that carry blood from the heart to the lungs. In other words, the arteries become constricted, and that makes it difficult for the blood to get to its destination.

An issue that has been plaguing Arena Pharmaceuticals for many years was the approval of its weight loss drug Belviq. The company had chosen to dump the drug over to its worldwide marketing partner Eisai. That means that Eisai took over all responsibility for selling Belviq in the market. The reason for the change, as noted by Arena, was so that it could instead focus on its pipeline. The therapeutic results posted on Monday in PAH prove that it was a wise move. Arena not only was able to shift focus to its pipeline, but it also received other benefits by getting rid of Belviq. First, Arena landed up to $23 million in cash payments. Secondly, it saved around $80 million or more in cost savings from walking away from the drug. The obesity market wasn’t just a tough nut to crack for Arena. Both Orexigen (OREX) and Vivus (VVUS) also faced hardships in the obesity market. In March of 2016, Takeda walked away from its deal with Orexigen. Vivus who decided to go solo selling its obesity drug has performed poorly as well. Despite this setback, Arena has pulled through with its latest clinical results. Not having to rely on Belviq is a good thing for the company.

According to the most recent 10-Q SEC filing, Arena has cash and cash equivalents of $79.5 million as of March 31, 2017. After the SEC filing, Arena raised around $79.4 million in April of 2017. Arena offered to sell 69 million shares at a price of $1.15 per share. The company now has enough cash to last for the next 12 months. That is a big problem because biotech companies with one years worth of cash don’t wait until the end to dilute. There will likely be a cash raise within the next few months which would put some pressure on the stock.

There are quite a few risks for those who are investing in Arena Pharmaceuticals. One such risk is that while the phase 2 results were positive, that doesn’t automatically mean that the phase 3 results will come out the same way. Without finding an adequate partnership for another product in the pipeline Arena will have to raise cash one way or another. That might involve taking on debt or diluting shareholders. Even if the company passes a phase 3 trial with Ralinepag there is no guarantee that the FDA will approve the drug in its current form.

Arena Pharmaceuticals has posted positive results in a phase 2 trial treating patients with PAH. That provides these patients the ability to take an oral drug instead of having to go through an intravenous infusion. These positive results point to a major shift for Arena as a biotechnology company. Dumping Belviq over to Eisai just might have saved the company from collapsing.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.





The New North American Marijuana Stock Basket, Seeking Alpha, arena pharmaceuticals stock.#Arena #pharmaceuticals #stock

arena pharmaceuticals stock

Arena pharmaceuticals stock

The Daily Marijuana Observer

The New North American Marijuana Stock Basket

Aug. 24, 2017 6:48 AM

  • Back in April, we covered the recently IPO’ed marijuana ETF, and the basket of underlying cannabis companies that make up its portfolio.
  • Since then, the ETF’s underlying index has been re-balanced, and there is a new basket of cannabis stocks to look at.
  • We walk you through the new basket of cannabis companies, how it’s weighted, and suggest another way you can weight your basket as well.

Background

Let’s face it, everyone is interested in what’s going on in the cannabis industry. Whether or not people are personally interested in consuming marijuana, it can be difficult to ignore the massive growth potential of this space.

As the number of companies operating in the sector continues to grow at an astounding rate, it can be tough for the average investor to peg the individual winners and losers.

Arena pharmaceuticals stock

On Wednesday, April 5th the Horizons Medical Marijuana Life Sciences ETF (TSX:HMMJ) began trading on the TSX. HMMJ was the first-of-its-kind ETF offing investors direct exposure to a basket of marijuana-related companies based in Canada and the United States.

In June, Horizons announced that they’d be cutting the word medical from the fund’s name to reflect upcoming changes in Canada’s recreational marijuana laws and thus expand its investment objective to include a larger potential group of companies.

The re-named Horizons Marijuana Life Sciences ETF seeks to track the Solactive North American Medical Marijuana Index, which currently has 18 top-notch cannabis-focused constituents. HMMJ however gives investors exposure to 21 of the top cannabis companies in North America, as of data from August 22nd.

Since the ETF has more companies in its portfolio than the index, we’ll go over the ETF’s components to give investors an idea of 21 leaders in the space.

Marijuana ETF Components

Back in April, the ETF was tracking 16 different companies. While a majority of the components have remained, new companies have been added and weightings have changed substantially since then.

The cannabis companies that make up the Horizons Marijuana Life Sciences ETF (in order of weighting from highest to lowest) are as follows:

  • Aurora Cannabis Inc. (OTCQX:ACBFF)
  • Canopy Growth Corp. (OTCPK:TWMJF)
  • Aphria Inc. (OTCQB:APHQF)
  • Scotts Miracle-Gro Co. (SMG)
  • GW Pharmaceuticals Plc. (GWPH)
  • Insys Therapeutics Inc. (INSY)
  • Cronos Group Inc. (OTCPK:PRMCF)
  • Organigram Holdings Inc. (OTCQB:OGRMF)
  • Supreme Pharmaceuticals Inc. (OTCPK:SPRWF)
  • Cannimed Therapeutics Inc. (OTC:CMMDF)
  • Arena Pharmaceuticals Inc. (ARNA)
  • 22nd Century Group Inc. (XXII)
  • Emblem Corp. (OTCPK:EMMBF)
  • Emerald Health Therapeutics (OTCQX:EMHTF)
  • ICC International Cannabis Corp. (OTC:ICCLF)
  • Zynerba Pharmaceuticals Inc. (ZYNE)
  • Hydropothecary Corp. (OTC:HYYDF)
  • Maricann Group Inc. (OTCQB:MRRCF)
  • Invictus MD Strategies Corp. (OTCPK:IVITF)
  • ABcann Global Corp. (OTCQB:ABCCF)
  • MedReleaf Corp. (OTCPK:MEDFF)

Which Companies Were Removed?

Companies that were removed include Cannaroyalty Corp. (OTCQX:CNNRF) and Maple Leaf Green World (OTCQB:MGWFF). Companies that were added include 22nd Century, ABcann Global, Arena Pharmaceuticals and more.

Investing in the Basket vs. Individual Companies

This article was meant to help investors utilize the diversified basket approach to investing in the cannabis sector. On the other hand, investors trying to pick individual winner companies out of the basket should be sure to conduct ample due diligence first and make sure your risk profile and time horizon are in-line with that of the company.

For instance, some of the aforementioned component companies have major stakes in late-stage applicants to become licensed producers of medical cannabis under Health Canada’s ACMPR process. This makes for a great upside if Health Canada gives them the green light or if they are acquired, but offers potential for downside if the application were to have issues or be denied.

Also worth noting for those deviating from the diversified basket is the fact that some of the companies in the portfolio have contradictory interests in the cannabis movement. These opposing interests can lead to inverse correlations in the markets, thus decreasing volatility for the portfolio. The most obvious example of this is the interests of pharmaceutical companies vs. the cannabis cultivator companies. Insys alone spent half a million dollars to fight legalization in the last election.

Basket Replication

First we’ll start by replicating the Horizons Marijuana Life Sciences ETF for those who want to closely track the newly launched ETF while still allowing for profit taking in an individual name if the opportunity arrises. The ETF’s component companies (in weighting order) and weights as of the close on August 22nd are as follows:





TEVA Stock Price – News – Teva Pharmaceutical Industries Ltd, teva pharmaceuticals stock.#Teva #pharmaceuticals #stock

Teva Pharmaceutical Industries Ltd. ADR

Nov 30, 2017 4:02 p.m. ET EST

Loading more news…

There is no more news available.

  • Nov 29, 2017 New Migraine Drugs Show Promise in Race to Sell Next-Generation Treatments The Wall Street Journal
  • Nov 28, 2017 Teva shares surge on corporate shake-up MarketWatch.com
  • Nov 27, 2017 Teva’s New CEO Starts Turnaround Plan at Struggling Drugmaker The Wall Street Journal
  • Nov 27, 2017 Stocks to Watch: Amazon, Time, Alkermes, Biogen, SandRidge, Barracuda Networks WSJ Blogs
  • Nov 10, 2017 Why tax-bill fears may be one big contributing factor in junk bond slump MarketWatch.com
  • Nov 8, 2017 Teva’s stock and bonds walloped after Fitch downgrade to junk MarketWatch.com
  • Nov 7, 2017 Why Mallinckrodt’s Woes Matter to All Drug Makers The Wall Street Journal
  • Nov 7, 2017 Teva’s latest quarter was even worse than already-low expectations MarketWatch.com
  • Nov 6, 2017 A Rare Bright Spot for Mylan The Wall Street Journal
  • Nov 2, 2017 Teva’s Rebuild Is Going Nowhere The Wall Street Journal
  • Nov 2, 2017 Teva Cuts Outlook Again in Perfect Storm of Problems The Wall Street Journal
  • Nov 2, 2017 Teva earnings: Facing down cheaper generic prices, generic competition of its own and a lot of debt MarketWatch.com
  • Nov 1, 2017 Another Headache for Teva Shareholders WSJ Blogs
  • Oct 31, 2017 States Expand Price-Fixing Accusations Against Generic Drug Companies The Wall Street Journal
  • Oct 23, 2017 Allergan: That $15 Billion Sure Went Fast The Wall Street Journal
  • Oct 23, 2017 Dividend Fears Take Toll on GE Shares The Wall Street Journal
  • Oct 17, 2017 Impax Laboratories and Amneal Pharmaceuticals Agree to Merge The Wall Street Journal
  • Oct 16, 2017 Impax Laboratories and Amneal Pharmaceuticals Near Merger Agreement The Wall Street Journal
  • Oct 16, 2017 Allergan Loses Patent Fight in Federal Court The Wall Street Journal
  • Oct 16, 2017 Lost beneath headlines of five-figure drug costs — pharmaceutical price growth is weakening MarketWatch.com

Loading more news…

There is no more news available.

  • Nov 29, 2017 The New England Journal of Medicine Publishes Data from Pivotal Phase III Trial of Fremanezumab for the Preventive Treatment of Chronic Migraine PR Newswires
  • Nov 27, 2017 Teva Announces New Organization Structure and Leadership Changes PR Newswires
  • Nov 15, 2017 Teva Announces Prescription Copay Savings Program for Generic Gleevec(R) Tablets in the United States PR Newswires
  • Nov 2, 2017 Teva Announces Completion of Plan B One-Step(R) Divestiture to Foundation Consumer Healthcare PR Newswires
  • Nov 2, 2017 Teva Reports Third Quarter 2017 Financial Results PR Newswires
  • Nov 1, 2017 Teva Announces Completion of PARAGARD(R) Divestiture to CooperSurgical PR Newswires
  • Nov 1, 2017 FDA s Efforts to Accelerate New Drug Development is a Big Bonus for Biotech and Pharma Stocks PR Newswires
  • Oct 31, 2017 Teva Wins Generic Uceris(R) Patent Trial PR Newswires
  • Oct 30, 2017 Kåre Schultz to Join Teva as President and Chief Executive Officer on November 1, 2017 PR Newswires
  • Oct 26, 2017 Teva to Highlight Asthma Data at the 2017 American College of Allergy, Asthma and Immunology Annual Scientific Meeting PR Newswires
  • Oct 23, 2017 Glancy Prongay Murray Reminds Investors of the October 23rd Deadline in the Class Action Lawsuit Against Teva Pharmaceutical Industries Ltd. (TEVA) PR Newswires
  • Oct 19, 2017 Teva to Highlight New Data in Multiple Sclerosis at Joint ECTRIMS — ACTRIMS Congress in Paris PR Newswires
  • Oct 18, 2017 TEVA Reminder Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Teva Pharmaceutical Industries Ltd. PR Newswires
  • Oct 18, 2017 Clinical Trials and Advanced Development of Innovative Drug Treatments Boosting Biotech Sector Gains PR Newswires
  • Oct 17, 2017 Teva Announces Submission of Biologics License Application for Fremanezumab to the U.S. FDA PR Newswires
  • Oct 14, 2017 DEADLINE ALERT: Brower Piven Reminds Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Teva Pharmaceutical Industries Limited to Contact the Firm PR Newswires
  • Oct 11, 2017 INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Teva Pharmaceutical Industries Ltd. Investors and Encourages Investors to Contact the Firm (TEVA) PR Newswires
  • Oct 10, 2017 Teva to Report Third Quarter 2017 Financial Results on November 2, 2017 PR Newswires
  • Oct 6, 2017 TEVA PHARMACEUTICAL SHAREHOLDER ALERT: ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Teva Pharmaceutical Industries Limited – (TEVA) PR Newswires
  • Oct 5, 2017 Teva Announces tomy s Award Winner at Oncology Satellite Symposium During the 7(th) International Symposium on Acute Promyelocytic Leukemia (APL) in Rome, Italy PR Newswires

Loading more news…

There is no more news available.

Major Holders

Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source: FactSet Fundamentals

Feedback on our new quotes?EMAIL US

Key Stock Data

Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company, which provides patient-centric healthcare solutions.

Key Executives

Competitors (TEVA)

Real-time U.S. stock quotes reflect trades reported through Nasdaq only.

International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times.

Quote data, except U.S. stocks, provided by SIX Financial Information.

Data is provided as is for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

All of the mutual fund and ETF information contained in this display was supplied by Lipper, A Thomson Reuters Company, subject to the following: Copyright 2017 © Thomson Reuters. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Bond quotes are updated in real-time. Source: Tullett Prebon.

Currency quotes are updated in real-time. Source: Tullet Prebon.

Fundamental company data and analyst estimates provided by FactSet. Copyright 2017 FactSet Research Systems Inc. All rights reserved.





Delhi – Latest News, Politics, Events, Entertainment – The Hindu, kv pharmaceutical stock.#Kv #pharmaceutical #stock

Delhi tops metros in crime against women

Despite the marginal dip it witnessed in crime against women, Delhi continued to record the highest number of such cases in 2016 among metropolitan

Kv pharmaceutical stock

Delhi-Union government spat: ‘Executive power rests with Centre’

Kv pharmaceutical stock

40 families left homeless after CPWD demolition drive

Kv pharmaceutical stock

Now, Rewari schoolgirls brace for battle over teachers

Kv pharmaceutical stock

Packed bus catches fire, all passengers evacuated

Kv pharmaceutical stock

Endangered vulture rescued from temple

Kv pharmaceutical stock

HC annoyed over govt proposal to buy buses from green cess

Life & Style

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Opening up space

Black Box Okhla is an emerging space in the city that is all about exploring the voids in a mill shell

Multimedia

Kv pharmaceutical stock

Smog-hit Delhi gets no respite on Friday

Kv pharmaceutical stock

With a thick haze, Delhi in a daze

Kv pharmaceutical stock

One year of demonetisation: Youth Congress protests outside RBI office, labels it ‘black day’

Kv pharmaceutical stock

Delhi in the grip of smog

Entertainment All

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Mona Singh’s photo exhibition ‘Innocence’: in the light of true carpe diem

Delhi-based street photographer Mona Singh celebrates pockets of purity through her photography show ‘Innocence’

SC clears release of film based on Kejriwal’s life

Says freedom of speech and expression is sacrosanct

Drifting through time and memory

Delhi artist Sumedh Rajendran on the invisible spaces and moments that fall between the cracks of life

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Sport All

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Fire in Delhi hotel where Dhoni, teammates were staying

The match that was supposed to be held at the Airforce ground in Palam has been rescheduled at Feroz Shah Kotla on Saturday after match referee Sanjay Verma announced the postponement.

Society

Kv pharmaceutical stock

Common name, uncommon stories

While remembering the many Mariams that lived in Delhi and surrounding areas, the tale of Sunny-ki-Mariam stands out





Teva stock plummets 18% after rough quarter in US generic drug market, teva pharmaceuticals stock.#Teva

Teva stock plummets 18% after rough quarter in US generic drug market

Teva pharmaceuticals stock

Shares of Teva Pharmaceutical fell more than 18 percent in morning trading Thursday after the company reported lower-than-expected second-quarter earnings.

div > div.group > p:first-child”>

Teva missed estimates for both earnings per share and revenue, and interim CEO Yitzhak Peterburg blamed the poor performance on a saturation of the U.S. generic drug market.

“[Teva] experienced … greater competition as a result of an increase in generic drug approvals by the U.S. FDA,” Peterburg said in the earnings release. He added that “customer consolidation” hurt sales in the U.S., before saying competition hurt new product launches, some of which were delayed in the recent quarter.

Earnings per share of $1.02 was 4 cents below what analysts surveyed by Reuters expected. Revenue also fell short of analyst forecasts by more than $300 million, coming in at $5.686 billion compared to the expected $5.718 billion.

Peterburg said instability in the Venezuelan bolivar had a material effect, reducing revenue by $183 million compared to the same quarter last year.

On June 28, Peterburg warned that the global health-care industry faces a “huge disruption,” saying at the World Economic Forum that he believes “it will affect” the pharmaceutical industry.

Teva Pharmaceutical, headquartered in Israel, calls itself the largest producer of generic medicines. In specialty medicines, Teva has treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system.

The pharmaceutical company lost its CEO on February 7 when Erez Vigodman resigned suddenly amid reports of a bribery investigation by the Israel Police. The biggest company in Israel, Teva allegedly paid bribes into the hundreds of millions of dollars and falsified documents in order to hide them.

Teva’s stock fell more than 14 percent in pre-market, before continuing to decline after the market open. Shares of the company were down nearly 14 percent this year ahead of Thursday’s open.

Teva pharmaceuticals stock





TEVA Stock Price – News – Teva Pharmaceutical Industries Ltd, teva pharmaceuticals stock.#Teva #pharmaceuticals #stock

Teva Pharmaceutical Industries Ltd. ADR

Nov 30, 2017 4:02 p.m. ET EST

Loading more news…

There is no more news available.

  • Nov 29, 2017 New Migraine Drugs Show Promise in Race to Sell Next-Generation Treatments The Wall Street Journal
  • Nov 28, 2017 Teva shares surge on corporate shake-up MarketWatch.com
  • Nov 27, 2017 Teva’s New CEO Starts Turnaround Plan at Struggling Drugmaker The Wall Street Journal
  • Nov 27, 2017 Stocks to Watch: Amazon, Time, Alkermes, Biogen, SandRidge, Barracuda Networks WSJ Blogs
  • Nov 10, 2017 Why tax-bill fears may be one big contributing factor in junk bond slump MarketWatch.com
  • Nov 8, 2017 Teva’s stock and bonds walloped after Fitch downgrade to junk MarketWatch.com
  • Nov 7, 2017 Why Mallinckrodt’s Woes Matter to All Drug Makers The Wall Street Journal
  • Nov 7, 2017 Teva’s latest quarter was even worse than already-low expectations MarketWatch.com
  • Nov 6, 2017 A Rare Bright Spot for Mylan The Wall Street Journal
  • Nov 2, 2017 Teva’s Rebuild Is Going Nowhere The Wall Street Journal
  • Nov 2, 2017 Teva Cuts Outlook Again in Perfect Storm of Problems The Wall Street Journal
  • Nov 2, 2017 Teva earnings: Facing down cheaper generic prices, generic competition of its own and a lot of debt MarketWatch.com
  • Nov 1, 2017 Another Headache for Teva Shareholders WSJ Blogs
  • Oct 31, 2017 States Expand Price-Fixing Accusations Against Generic Drug Companies The Wall Street Journal
  • Oct 23, 2017 Allergan: That $15 Billion Sure Went Fast The Wall Street Journal
  • Oct 23, 2017 Dividend Fears Take Toll on GE Shares The Wall Street Journal
  • Oct 17, 2017 Impax Laboratories and Amneal Pharmaceuticals Agree to Merge The Wall Street Journal
  • Oct 16, 2017 Impax Laboratories and Amneal Pharmaceuticals Near Merger Agreement The Wall Street Journal
  • Oct 16, 2017 Allergan Loses Patent Fight in Federal Court The Wall Street Journal
  • Oct 16, 2017 Lost beneath headlines of five-figure drug costs — pharmaceutical price growth is weakening MarketWatch.com

Loading more news…

There is no more news available.

  • Nov 29, 2017 The New England Journal of Medicine Publishes Data from Pivotal Phase III Trial of Fremanezumab for the Preventive Treatment of Chronic Migraine PR Newswires
  • Nov 27, 2017 Teva Announces New Organization Structure and Leadership Changes PR Newswires
  • Nov 15, 2017 Teva Announces Prescription Copay Savings Program for Generic Gleevec(R) Tablets in the United States PR Newswires
  • Nov 2, 2017 Teva Announces Completion of Plan B One-Step(R) Divestiture to Foundation Consumer Healthcare PR Newswires
  • Nov 2, 2017 Teva Reports Third Quarter 2017 Financial Results PR Newswires
  • Nov 1, 2017 Teva Announces Completion of PARAGARD(R) Divestiture to CooperSurgical PR Newswires
  • Nov 1, 2017 FDA s Efforts to Accelerate New Drug Development is a Big Bonus for Biotech and Pharma Stocks PR Newswires
  • Oct 31, 2017 Teva Wins Generic Uceris(R) Patent Trial PR Newswires
  • Oct 30, 2017 Kåre Schultz to Join Teva as President and Chief Executive Officer on November 1, 2017 PR Newswires
  • Oct 26, 2017 Teva to Highlight Asthma Data at the 2017 American College of Allergy, Asthma and Immunology Annual Scientific Meeting PR Newswires
  • Oct 23, 2017 Glancy Prongay Murray Reminds Investors of the October 23rd Deadline in the Class Action Lawsuit Against Teva Pharmaceutical Industries Ltd. (TEVA) PR Newswires
  • Oct 19, 2017 Teva to Highlight New Data in Multiple Sclerosis at Joint ECTRIMS — ACTRIMS Congress in Paris PR Newswires
  • Oct 18, 2017 TEVA Reminder Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Teva Pharmaceutical Industries Ltd. PR Newswires
  • Oct 18, 2017 Clinical Trials and Advanced Development of Innovative Drug Treatments Boosting Biotech Sector Gains PR Newswires
  • Oct 17, 2017 Teva Announces Submission of Biologics License Application for Fremanezumab to the U.S. FDA PR Newswires
  • Oct 14, 2017 DEADLINE ALERT: Brower Piven Reminds Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Teva Pharmaceutical Industries Limited to Contact the Firm PR Newswires
  • Oct 11, 2017 INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Teva Pharmaceutical Industries Ltd. Investors and Encourages Investors to Contact the Firm (TEVA) PR Newswires
  • Oct 10, 2017 Teva to Report Third Quarter 2017 Financial Results on November 2, 2017 PR Newswires
  • Oct 6, 2017 TEVA PHARMACEUTICAL SHAREHOLDER ALERT: ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Teva Pharmaceutical Industries Limited – (TEVA) PR Newswires
  • Oct 5, 2017 Teva Announces tomy s Award Winner at Oncology Satellite Symposium During the 7(th) International Symposium on Acute Promyelocytic Leukemia (APL) in Rome, Italy PR Newswires

Loading more news…

There is no more news available.

Major Holders

Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source: FactSet Fundamentals

Feedback on our new quotes?EMAIL US

Key Stock Data

Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company, which provides patient-centric healthcare solutions.

Key Executives

Competitors (TEVA)

Real-time U.S. stock quotes reflect trades reported through Nasdaq only.

International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times.

Quote data, except U.S. stocks, provided by SIX Financial Information.

Data is provided as is for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

All of the mutual fund and ETF information contained in this display was supplied by Lipper, A Thomson Reuters Company, subject to the following: Copyright 2017 © Thomson Reuters. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Bond quotes are updated in real-time. Source: Tullett Prebon.

Currency quotes are updated in real-time. Source: Tullet Prebon.

Fundamental company data and analyst estimates provided by FactSet. Copyright 2017 FactSet Research Systems Inc. All rights reserved.





Megger Electrical Testers – Meters for Sale, Transcat, kv pharmaceutical stock.#Kv #pharmaceutical #stock

Megger Electrical Test Equipment

Do you have an electrical test or measurement challenge? Megger one of the industry s most recognizable brands has a full-service solution. The company has been a leading global provider of test equipment and measuring instruments for electrical power applications for over 100 years, and has been so influential in the creation and development of electrical insulation testers that the term Megger has become synonymous with these devices. The company is resolute in providing solutions that serve highly critical areas, such as: ground resistance and insulation testing, cable fault locating, and power quality testing.

Transcat is proud to be the industry s largest Megger distributor, with a unique suite of services to equip electricians, technicians and engineers with the world s foremost Megger instruments. In addition to hundreds of Megger instruments, we offer electrical calibration services and Megger instrument repair services as your full-service Megger solution.

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock

Kv pharmaceutical stock





ALPMY Stock Price & News – Astellas Pharma Inc #pharma #jobs

#astellas pharma

#

Astellas Pharma Inc. ADR ALPMY (U.S. OTC)

P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock’s most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period. Earnings Per Share (TTM) A company’s net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock’s price. For companies with multiple common share classes, market capitalization includes both classes. Shares Outstanding Number of shares that are currently held by investors, including restricted shares owned by the company’s officers and insiders as well as those held by the public. Public Float The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded. Dividend Yield A company’s dividend expressed as a percentage of its current stock price.

Key Stock Data

P/E Ratio (TTM)
EPS (TTM)
Market Cap
Shares Outstanding
Public Float
Yield

ALPMY has not issued dividends in more than 1 year.

Latest Dividend
Ex-Dividend Date

Shares Sold Short The total number of shares of a security that have been sold short and not yet repurchased. Change from Last Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month. Percent of Float Total short positions relative to the number of shares available to trade.

Short Interest ()

Money Flow Uptick/Downtick Ratio Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an “uptick” in price and the value of trades made on a “downtick” in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.

Stock Money Flow

Real-time U.S. stock quotes reflect trades reported through Nasdaq only.

International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times.

Quote data, except U.S. stocks, provided by SIX Financial Information.

Data is provided “as is” for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

All of the mutual fund and ETF information contained in this display was supplied by Lipper, A Thomson Reuters Company, subject to the following: Copyright © Thomson Reuters. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Bond quotes are updated in real-time. Source: Tullett Prebon.

Currency quotes are updated in real-time. Source: Tullet Prebon.

Fundamental company data and analyst estimates provided by FactSet. Copyright FactSet Research Systems Inc. All rights reserved.





The 5-Minute Guide to Horizon Pharma PLC Stock – The Motley Fool #pharma #regulatory

#horizon pharma

#

The 5-Minute Guide to Horizon Pharma PLC Stock

Value investors don’t need to know a mitochondria from a hole in the ground to sense something’s amiss with Horizon Pharmaceuticals (NASDAQ:HZNP ) stock. Over the past several years the company’s sales have exploded, yet the stock fallen roughly 50% from its peak last summer.

With a forward price-to-earnings ratio under 10, this looks like a bargain hunter’s dream come true. Before you go diving in, take five minutes to familiarize yourself with this company. You’ll be glad you did.

Pharma-funds
Even if you don’t follow pharmaceutical industry news, by now you’re probably familiar with “pharma-bro” Martin Shkreli. While CEO of Touring Pharmaceuticals he orchestrated an overnight 5,500% price hike of rare disease drug daraprim, and a media frenzy ensued.

While he took the practice to an extreme, his activity drew attention to an industry trend that had been taking place for years. Developing new drugs is risky, and as companies grow their returns on R D tend to shrink. Companies such as Valeant Pharmaceuticals. and Horizon Pharma, among others, realized that acquiring drugs that have already won approval, then unlocking their value through flawless execution of commercial strategy, is a viable business model. Imagine a fund manager able to purchase undervalued stocks, then set their prices as high as the market will bear on his own.

What some might call excessive price raising has led to unprecedented scrutiny of Valeant’s, as well as Horizon’s, relationships with certain specialty pharmaceutical distributors, and price raising practices. This scrutiny during an election year has devastated Valeant’s share price over the past several months, along with the SPDR S P Pharmaceuticals ETF (NYSEMKT:XPH ) of which Horizon Pharma is a top-ten holding.

Horizon Pharmaceuticals’ model isn’t identical to Valeant’s or Touring’s, but it isn’t terribly research heavy either. Since 2013, Horizon has increased its medicines portfolio from two products to nine, as of this January. The addition of those products sent Horizon’s sales through the roof, from just $18.8 million in 2012, to $757 million in 2015. Last year alone it began recognizing revenue from three recently acquired drugs — Pennsaid, Ravicti, and Buphenyl — adding $247.3 million its top line.

As its declining R D expense as a percentage of revenue shows, it didn’t develop those drugs itself. It acquired them, and ended 2015 with over $1.1 billion in debt. Last year it spent $69.9 million servicing those debts, and has some heavy contractual cash obligations in the years ahead. This year Horizon is on the hook for $92 million, and $74 million next year.

The $859.6 million in cash and equivalents on the books at the end of the 2015 might have helped its investors sleep easier. Following a $510 million acquisition of Crealta Holdings in January, much of the stuffing has fallen out of that pillow.

The products
Now that you know how Horizon leapfrogged into the big leagues, let’s look at some of the products. After all, their sales will be responsible for paying down those enormous debts, and hopefully generating some earnings. If you’re expecting some groundbreaking medical advances, you’re going to be disappointed. Last year, Horizon’s two best-selling products were combinations of drugs you can buy over-the-counter.

In first place was Duexis for relief of arthritic pain and prevention of gastric ulcers, which brought in $190 million, or 25% of Horizon’s total sales. It’s a combination of famotidine, which you’ll probably recognize by the brand name Pepcid, and ibuprofin.

Coming in second was Vimovo, also for relief of arthritic pain and ankylosing spondylitis, with sales of $166.7 million. It’s a combination of naproxen and esomeprazole magnesium, which you’ll probably recognize by their brand names, Aleve and Nexium.

Image source: Horizon Pharma PLC.

That’s right. Nearly half of the company’s revenue came from over the counter drugs combined into easy to administer pills. That convenience is expensive, and becoming more so. Pharmaceutical companies are not terribly forthcoming with pricing details, but recently the Centers for Medicare and Medicaid Services published some interesting information. In 2014, the annual change in average cost per unit of Vimovo rose 534% and cost Medicare Part D patients an average of $1,826 per beneficiary.

If you’re wondering why patients might be willing to shell out what must be a substantial co-pay, rather than swallow Pepsin or Nexium, before taking their ibuprofen or naproxen, let me introduce you to another standard practice in the pharmaceutical industry: Copay assistance programs. Out-of-pocket costs can be burdensome for patients, but with gross margins on pharmaceuticals so wide, companies are often willing “help” patients, then pocket enormous sums when the above-copay cost is covered by the insurance company.

Unwanted attention
Horizon Pharma’s extensive use of patient assistance programs, and relationships with specialty pharmacies hasn’t gone unnoticed by some authorities. Last November the company received a subpoena from the U.S. Attorney’s Office for the Southern District of New York requesting documents related to its patient assistance programs and other activities.

As bad as that may seem, the authorities may be the least of Horizon’s worries in the quarters ahead. America’s two largest pharmacy benefit managers Express Scripts. and CVS Health specifically exclude reimbursement for Duexis, and Vimovo, but some specialty pharmacies didn’t get the message. Express Scripts has been cracking down on specialty pharmacies that dispense formulary excluded drugs, and it will be interesting to see the effect on Horizon’s sales in the quarters ahead.

In transition
To be fair, Horizon’s more recent acquisitions, such as Krystexxa for treatment of gout in patients that no longer respond conventional therapy, look like an effort to reduce its dependance on aggressive price raising of drugs that aren’t terribly innovative. Also, a move to the low corporate tax haven of Ireland would do wonders to its bottom line. However, if sales of its top two drugs plummet there won’t be much profit to tax anyway.

Considering its debt pile however, transitioning to a company truly focused on innovation might be impossible. It will be fun to see what effect specialty pharma crackdowns and U.S. attorney investigations have on Horizon Pharma in the quarters ahead; from the sidelines, not as a shareholder.

Cory Renauer has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .





Pharmaceuticals Stock Price, Share Price, Live BSE #cipla #pharma

#pharma stocks

#

Pharmaceuticals

Indian Pharma sector has made rapid strides in both global and domestic market. But the growth pangs were severe for domestic players eyeing greater share of global pie. The slow down in generic approvals by USFDA, the payment problems witnessed in a few developing markets since the quarter ended December 2008 and accelerated genericisation and intense compe. more

Indian Pharma sector has made rapid strides in both global and domestic market. But the growth pangs were severe for domestic players eyeing greater share of global pie. The slow down in generic approvals by USFDA, the payment problems witnessed in a few developing markets since the quarter ended December 2008 and accelerated genericisation and intense competition together meant slower growth in global revenues for the domestic players. But despite challenging environment, the domestic players continued their consolidation mode and are getting ready for increased CRAMS business from the global majors. Attracted by enticing business model of the domestic pharma companies, some global players have acquired Indian pharma companies including Ranbaxy Laboratories, Matrix Laboratories etc. Simultaneously, we also witnessed global majors like Pfizer entering deal with domestic players like Aurobindo Pharma and Claris Lifesciences (unlisted) for marketing their generics in the advanced markets. Likewise, we are also witnessing increase in buy back / open offer for share holders of associates / subsidiaries of the MNC pharma companies. So, the pharma sector is in thick of action. With availability of skilled labour at low cost, India has become favorable destination for most of Multinational companies to manufacture their products and to develop new molecules. Consolidation has started in the Global Pharmaceutical industry with some mega merger proposals like Pfizer acquiring Wyeth, Merck & Co �Plough deal followed by Roche-Genetech deal etc. With many blockbuster drugs about to expire in the next 3-5 years and at the same time fall in the research pipeline has become major concern for the all MNC players. To maintain bottom-line, the top MNC companies are looking towards buying the generic players or partnership with generic player to market generic drugs in advanced markets. With huge cash in hand and attractive valuation, MNCs are also acquiring the majority stake in its emerging market subsidiaries in regular, India in particular. The MNC companies Novartis, Pfizer and Merck came with buy back proposal to acquire stake in their Indian Subsidiary. hide

updates





Raptor Pharmaceutical (RPTP) Stock Slumps, Said to be Exploring Sale #crm #pharma

#raptor pharma

#

Raptor Pharmaceutical (RPTP) Stock Slumps, Said to be Exploring Sale

NEW YORK (TheStreet ) — Shares of Raptor Pharmaceutical Corp. (RPTP ) are dipping by 5.85% to $5.47 on heavy trading volume Thursday afternoon, as the biopharmaceutical company is in talks with investment banks to hire a financial adviser to explore a possible sale, according to sources cited by Reuters after yesterday’s market close.

The move may not lead to a sale, the sources added.

JMP Securities upgraded the stock to “market outperform” from “market perform” and established a $9 price target following the report.

A sale of Raptor makes sense because it is almost a classic model for recent transactions where specialty pharma companies have purchased orphan disease companies, the firm said.

“Raptor has steady revenue from Procysbi, approved for cystinosis, and it will soon begin selling Quinsair, an antibiotic for cystic fibrosis in the EU and Canada. While the company could be quickly profitable on these assets alone, as an independent company, it must invest in R D to drive long-term growth, which is a drag on earnings,” JMP Securities wrote in a note.

A number of companies including Horizon Pharma (HZNP), Shire (SHPG) and Allergan (AGN) could be interested in the company, according to the firm.

Novato, CA-based Raptor is focused on developing and commercializing treatments for people affected by rare and debilitating diseases.

About 2.01 million of Raptor’s shares were traded by this afternoon compared to its average 30-day volume of 1.2 million shares per day.

Separately, TheStreet Ratings Team has a “Sell” rating with a score of D on the stock.

The company’s weaknesses can be seen in multiple areas, such as its weak operating cash flow and generally disappointing historical performance in the stock itself.





Ajanta Pharma Ltd stock quote, Ajanta Pharma Ltd company overview #pharma #stocks

#ajanta pharma

#

Ajanta Pharma Ltd (AJPH.NS)

Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world’s largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Learn more about Thomson Reuters products:

Information, analytics and exclusive news on financial markets – delivered in an intuitive desktop and mobile interface

Everything you need to empower your workflow and enhance your enterprise data management

Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks

Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology

The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs

The industry leader for online information for tax, accounting and finance professionals





Stock: Teva Pharmaceutical Industries (TEVA) #research #pharma

#barr pharma

#

Teva Pharmaceutical Industries (TEVA)

This article refers to the pharmaceutical company. For the Brazial real (BRL), see Brazilian Real (BRL) .

Barr Pharmaceuticals (formerly BRL) was the parent company for Barr Laboratories and Duramed Pharmaceuticals, Inc. before being acquired by Teva Pharmaceutical Industries (TEVA). Through its two subsidiaries the company produces roughly 75 different generic pharmaceuticals and 19 brand name pharmaceutical products, largely focused on women’s health and birth control.

On July 18th 2008, generic drug manufacturer Teva Pharmaceutical Industries (TEVA) announced it would buy Barr for $66.50 / share in cash and stock. Under the terms of the deal, each share of Barr common stock will be converted into $39.90 in cash and 0.6272 Teva American depositary receipts. Teva said it expects the deal to close in late 2008. [1]

Barr differentiates itself from the competitors in that it only seeks to formulate hard to reproduce brand name drugs, those with complex formulations or difficult to source materials. This strategy provides it with some measure of protection, by making it more difficult for other generics companies to replicate its products. The company may also benefit from overall growth in the generics market as Medicare and private insurance become increasingly receptive to generics, in the face of rising health care costs.

Contents

Business Financials

Barr makes most of its money from sales of generic products. Its sales of $1.3 billion in 2006 were about 75% from generic products and only 25% proprietary medications. As a subset of these areas, Barr’s most important therapeutic area is contraceptives and birth control. The striking difference between revenue and profits (net earnings) in the graphs could in part be caused by Barr’s increased marketing efforts of proprietary products in 2003-2004. Initial costs for marketing a product are very high, and as the patient base expands, these costs decrease meaning profits can increase.

An interesting strategy Barr employs is filing patent challenges first. If the challenge is successful, the company that filed the challenge receives 180 days of “exclusivity” wherein there is no competition from other generic producers.

Error creating thumbnail

Barr Annual Report [2]

Error creating thumbnail

Barr Annual Report [3]

Key Trends and Forces

*Towards Generic Drugs: The generic market has grown significantly in recent years. The percentage of overall prescriptions filled with generic products grew from 46.5% in 2000 to 57.3% by 2005 [4]. The aging population. rising health care costs, and insurance companies’ attempts to minimize costs could all contribute to a further increase in demand for generic products. Medicare spending could also play a significant role in the continued growth of the generics industry. The program which accounts for approx. 12% of the federal budget has been under pressure to cut costs. If Medicare moves to encourage greater use of generics, it would be a huge win for the industry and companies like BARR.

*Patent Expiration: Because Barr’s main focus is on generic drugs, one of the most important factors in determining its profitability are patent expirations of other companies’ successful medications. Pharmaceutical patents are generally short, and the process for gaining FDA Approval for a generic drug is much less rigorous than for a new medication. Often, generic manufacturers only have to prove that their product is equivalent. They do not have to go through the lengthy and expensive process of clinical trials.

When patents expire, often companies will attempt to reformulate products to maintain the patents. By adding new ingredients or changing the formula slightly, patent life can be extended, or brand domination can be maintained through the new formula. Thus, even if it appears that a patent will expire, there is no guarantee that this will really open up the market for generic manufacturers.

Error creating thumbnail

Barr Annual Report [5]

*Legal Challenges: Part of being a generic manufacturer means dealing with the “edge” of patents. That is, there is likely a gray area between when a product is protected by patent and when it is not. Because of this, companies such as Barr often face law suits from brand manufacturers. Currently, Barr has been fighting over patents on Yasmin, Ortho, Try-Cyclen Lo, and Allegra-D, which seem to be coming to an end soon.

*Brand Loyalty: Because patent laws allow brand name medications to monopolize the market for a certain number of years, brands have a chance to build loyalty and get people “hooked.” For example, if a patient is taking medication for a life-threatening condition, such as heart disease, doctors are unlikely to switch the patient to a new medication.

*Contraceptive Products: The market for contraceptives is especially important to Barr. One of its major products, the “morning after pill” called Plan-B, is very controversial in some areas. The product causes a fertilized egg not to implant itself in the uterus, and many claim that this is essentially a type of “pre-abortion.” Thus, legislation effecting abortion, as well as pharmacists’ ability to refuse to fill prescriptions, will effect sales of Plan-B. Also, there is constantly new research on side effects of oral contraceptives and hormones. If it is found that there are negative effects, Barr’s sales could suffer.

Competition

Because patent expiration means that any company can now access the formula of a medication and manufacture it, competition is fierce. Barr has a unique way of side-stepping some competition. It relies on four “qualifications” in deciding what products to produce. These include:

  1. Those with complex formulation or development characteristics;
  2. Those requiring specialized manufacturing capabilities;
  3. Those where sourcing the raw material may be difficult;
  4. Those that must overcome unusual regulatory or legal challenges, including patent challenges.

These conditions are designed to create generics that other companies cannot easily create. Barr goes after the more difficult products to manufacture, meaning that it will face less competition than if it went after easy products.

Error creating thumbnail

Company Annual Reports [6]

Barr’s major competitors including are:

  • Teva Pharmaceutical Industries (TEVA). Teva Pharmaceuticals USA is one if the largest producers of generic drugs. Its products include therapeutic areas such as anti-infective, cardiovascular, oncology, dermatological and anti-inflammatory.
  • Sandoz, a generic division of Novartis AG (NVS). Sandoz’s major therapeutic areas include antibiotics, preparations for treating the central nervous system, cardiovascular, hormones and antiallergics.
  • Mylan Laboratories (MYL) is the third largest generic producer in the US. Mylan also owns subsidiaries that produce proprietary drugs and hospital packages.
  • Dr. Reddy’s Laboratories (RDY) is one of the largest generic manufactures in the US by revenue. It also manufactures branded products. Dr. Reddy’s products include those for hypertension, allergies, urological disorders, cardiovascular, and antibiotics.

Notes





Free Business Card Maker: Make a Business Card for Free #how #to #make, #online, #make,


#

Easy-to-Use Business Card Maker

Try Our Free Business Card Maker – It’s Fast & Easy!

  • We’re Trusted – 25 million users worldwide have used our free templates.
  • High-Quality Designs – Our designers are expertly trained.
  • Fast & Easy Process – Make personalized business cards in minutes.
  • It’s Free – Make your business cards for free. Buy your favorite design.
  • Our Selection – Have we mentioned our 1,000s of business card options?

Make Your Cards

Do-It-Yourself Professional Business Cards

Make your own personalized business card today with our free business card maker. You can customize any of our 1,000+ business card designs, from colors and fonts, to text and layout. When you are ready to print your business card, buy your design and have unlimited access to your files.

What Our Customers Say About Our Business Cards

“FreeLogoServices is a tremendous value especially for new start-ups or small companies with limited marketing budgets. Their services make the process of designing a unique and professional Logo amazingly simple and easy. Loved the business card order process and quality of the cards delivered.” – Garrett Riley

Make a Logo for Your Business Card

Make a logo for your professional business card, at no additional cost. The award-winning designers at FreeLogoServices have created 1,000s of logos that you can use when you make a business card. Once you’ve finished your design with our free business card maker, purchase the files to get unlimited access to print as many cards as you need. Choose a matte or glossy finish, premium or ultra-premium paper stock, and even add a custom design to the back of your cards.

Popular Business Card Categories:


GE Stock Price & News – General Electric Co #general #electric #co. #stock #price, #general


#

General Electric Co. GE (U.S. NYSE)

P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock’s most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period. Earnings Per Share (TTM) A company’s net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock’s price. For companies with multiple common share classes, market capitalization includes both classes. Shares Outstanding Number of shares that are currently held by investors, including restricted shares owned by the company’s officers and insiders as well as those held by the public. Public Float The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded. Dividend Yield A company’s dividend expressed as a percentage of its current stock price.

Key Stock Data

P/E Ratio (TTM)
EPS (TTM)
Market Cap
Shares Outstanding
Public Float
Yield
Latest Dividend
Ex-Dividend Date

Shares Sold Short The total number of shares of a security that have been sold short and not yet repurchased. Change from Last Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month. Percent of Float Total short positions relative to the number of shares available to trade.

Short Interest (05/31/17)

Shares Sold Short
Change from Last
Percent of Float

Money Flow Uptick/Downtick Ratio Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an “uptick” in price and the value of trades made on a “downtick” in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.

Stock Money Flow

Uptick/Downtick Trade Ratio

Real-time U.S. stock quotes reflect trades reported through Nasdaq only.

International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times.

Quote data, except U.S. stocks, provided by SIX Financial Information.

Data is provided “as is” for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

All of the mutual fund and ETF information contained in this display was supplied by Lipper, A Thomson Reuters Company, subject to the following: Copyright © Thomson Reuters. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Bond quotes are updated in real-time. Source: Tullett Prebon.

Currency quotes are updated in real-time. Source: Tullet Prebon.

Fundamental company data and analyst estimates provided by FactSet. Copyright FactSet Research Systems Inc. All rights reserved.


Stock trade website #technical #analysis, #charts, #financial #charts, #sharpcharts, #point #and #figure, #yield #curve, #seasonality,


#

The Charting Tools and Resources You Need to Invest Smarter.

We make it easy to see what’s really happening in the markets.

Trusted by thousands of online investors worldwide, StockCharts.com makes it easy to create the web’s highest-quality financial charts in just a few simple clicks. Annotate your charts, save them to your account, and access them on-the-go from any web-enabled device. Start free and see how StockCharts can help you take control of your investing.

Sign up for a free 1-month trial today!

The “Bread and Butter” Chart

Traditional daily OHLC bars with 50-day and 200-day Moving Averages and Y-Axis labels showing you exact values on the chart’s right side

Price Labels For Peaks and Troughs

Our “Sunset” color scheme with Japanese Candlesticks and Price Labels that display price data at significant highs and lows on the chart

Auto-Generated Retracements

ZigZag Retracments point out significant price peaks and troughs and help identify chart patterns while automatically displaying percent changes

Candlesticks with Bollinger Bands

Japanese Candlesticks for short-term trading patterns combined with area-filled Bollinger Bands that show when prices get “out of whack”

Market Breadth Charts

Visualize market participation with breadth charts, such as the number of NYSE stocks making new highs minus those making new lows

Moving Average Ribbons Chart

Multiple Moving Averages in different durations plotted on the same chart to help you visualize changing trends in a security’s price movement

Long-Term Gold Charts

The long-term trends of Gold prices show clearly on this log-scale monthly chart with data going all the way back to 1980

Point Figure Charts

Filter out market noise and stay focused only on significant price moves with our P F Charts, automatically plotted with 45-degree trendlines

Relative Rotation Graphs (RRG)

Visualize relative strength and momentum for a specific group of securities and catch new moves as they develop with RRG Charts

Interactive PerfCharts

Dynamically compare the performance of up to 10 different ticker symbols on the same chart to see relative strength within a group of securities

Seasonality Charts

A favorite among StockCharts users, Seasonality Charts display monthly price performance trends over an adjustable period of time

3 Unique Membership Options To Help You Invest Smarter.

Save $39.95!

US $479.40 per year + 1 month free
  • 25 Technical Indicators per Chart
  • 25 Technical Overlays per Chart
  • Intraday Charting
  • Available Real-Time Data
  • Huge, Full-Screen Charts
  • 5-Second Auto Refresh
  • Historical Price Data Back to 1900
  • Quarterly Yearly Charts
  • 350 ChartLists (500 charts / list)
  • Even More Access to ChartPacks
  • 300 Custom Scans
  • 50 Custom Alerts
  • 10 Price Datasets per Chart
  • Customizable RRG Charts
  • Members-Only Commentary
  • Web Email Support
How Your Free Trial Works

Free trial accounts begin at our Extra service level. You may upgrade or downgrade to other service levels during the trial period. You may cancel your free trial at any time and will not be charged. Unless cancelled, your account will automatically renew at the end of your free trial for another month of your most recently selected service level.

Have you been a StockCharts Member within the past year?

Frequently Asked Questions

How does the free 1-month trial work?

With our trial, the first month of service is totally free. You may cancel at any time during the trial month and will not be billed. All new trial accounts begin at our Extra service level, but you may upgrade or downgrade at any point during the free month. After that period, we will charge your credit card for another month of whichever service level you last selected. Refunds are available only for whole months of service and do not apply to data plans.

Can I change subscription plans during my 1-month trial period?

Yes, you can upgrade or downgrade to any of our membership plans during the 1-month free trial period. At the end of the trial, we will charge your credit card for another month of whichever service level you last selected.

Do I have to sign up for a long-term contract?

No. StockCharts accounts are typically billed on a month-to-month basis. If you cancel, you will be billed for the current month but you won’t be billed again. You do also have the option to sign up for an annual billing plan, which allows you to prepay for 12 months of StockCharts service and receive the 13th month free of charge.

Will I also have to pay exchange fees?

You have the option to add official real-time data for the US, Canada, the UK and India to your account. The official exchange fees for the country (or countries) that you select will be billed to your account in addition to the cost of your monthly StockCharts membership.

What payment methods do you accept?

Currently we accept Visa, Mastercard, American Express and Discover. We are only able to accept online payments at this time.

How long can I subscribe for?

We have two billing options: monthly or annual. If you sign up for our monthly billing option, you will be automatically billed each month for the service level that you choose. With our annual billing option, you will be billed for 12 months of whichever service level you choose and receive the 13th month free of charge.

What types of charts can I create?

StockCharts allows you to create intraday, daily, weekly, monthly, quarterly and yearly Price Charts, Point Figure Charts, Seasonality Charts, Relative Rotation Graphs (RRG), Interactive PerfCharts, and more.

I’m a previous member. Can I re-activate my old account?

Absolutely! We’re happy to have you back. If you’ve been a StockCharts Member within the past year, we should still have all of your saved charts, scans and other information. Click here to restore your expired StockCharts account!

Which exchanges does StockCharts cover?

We provide high-quality financial charts for US stocks (NYSE, NASDAQ, AMEX), US Mutual Funds, Canadian stocks (TSX, Venture), UK stocks (LSE) and Indian stocks (NSE). We also provide over 1000 technical market indicators and indexes as well as end-of-day charts for most US commodity contracts.

Do you provide real-time streaming charts?

We provide real-time charts that automatically update just like streaming charts, but without forcing you to install complicated software packages or browser plugins. Our charts automatically refresh every 5 seconds (Pro) or 15 seconds (Extra Basic). However, they can be manually refreshed as often as you need just by clicking the “Update” button.

Does StockCharts work on an iPad or an iPhone?

It sure does! Our standard website is mobile-friendly and has been optimized to work well in the browser of all your iOS devices.

Where can I ask more questions before I sign up?

Visit our Support Center for answers to all your StockCharts-related questions, or Click Here to send a question to our Support Team.

Do you have free charts and tools for me to use if I’m not ready to sign up?

Absolutely. If you’re not ready to sign up for a free trial yet, we encourage you to check out our free charts, tools, resources and commentary. We have a wide array of features available for you to use for free, with no account necessary. To browse our free charting tools and resources, visit our Free Charts page. To read free expert market commentary from our content contributors, visit our Blogs page .


NYPD boycotts Dunkin as cops allegedly refused service, Daily Mail Online, buy dunkin donuts stock.#Buy


#

NYPD boycotts Dunkin’ Donuts after officers were allegedly refused service BUT the store’s manager claims that the cops didn’t wait in line to order

By Matthew Wright For Dailymail.com 21:00 BST 05 Aug 2017, updated 16:44 BST 06 Aug 2017

Buy dunkin donuts stock

  • On Sunday two plain clothed cops went into a Brooklyn, New York, Dunkin’ Donuts/Baskin-Robbins to buy ice cream
  • But they claimed that a store clerk ignored them – the manager claims video shows the officers were not standing in line and just waited at the pickup register
  • In response, the detectives union called for an NYPD boycott and an apology from the chain
  • At locations across the city, employees have made note of the shift in their sales to law enforcement

NYPD cops were boycotting Dunkin’ Donuts on Friday to protest the treatment of two officers who were allegedly refused service by an employee in one of the chain’s stores.

On Sunday, two plain clothed cops who were working the 73rd Precinct’s detective squad went into a Brooklyn, New York, Dunkin’ Donuts/Baskin-Robbins to buy ice cream. But they claimed that a store clerk ignored them.

‘I don’t serve cops,’ he said, according to a law-enforcement source who spoke with the New York Post.

In response, the detectives union called for an NYPD boycott and an apology from the chain.

At locations across the city, employees have made note of the shift in their sales to law enforcement.

The location on West 48th Street and Seventh Avenue told the Post it normally sells donuts and coffee to about 20 officers, daily.

‘[There were] actually none today,’ the worker said.

A Dunkin’ Donuts on West 40th Street near Seventh Avenue experienced similar set backs.

‘Today I did not see [them],’ said store worker Setu Mallick.

‘There are usually maybe four or five.’

The union has demanded that the shop’s corporate parents issue an apology for the alleged incident.

‘Since the story was reported, the union office received a lot of feedback from active and retired members supporting the boycott,’ said Michael Palladino, head of the Detectives Endowment Association.

‘I know that Dunkin Donuts supports law enforcement, which is why I am disappointed that their official statements are weak and suggest denial.’

On Thursday, a manager at the store spoke with the New York Post, discrediting the account shared by the officers and their source.

He said: ‘These two men in shirts and ties — who I later found out were police — must have never come to this Dunkin’ Donuts before, because instead of waiting in the line where you order, they waited at the counter where you pick up your order.

‘You can see on the security tape: they stand here for five minutes, while other customers were being served.

‘One customer even ordered ice cream, and they must’ve not like that because they left the store.’

While the manager wouldn’t share the video, he did say that the store was receiving calls from people claiming to be police and asking, ‘Why didn’t you serve these officers?’

The manager added: ‘And I kept trying to explain that we serve everyone, we have nothing but respect for the police, and that they were standing at the wrong counter.

‘It was busy at the time, and we were busy serving customers.’

An email from an executive at the popular chain blasted an email to New York franchise owners, telling them not to speak with press.

‘By now you are probably aware of a news situation concerning two New York City police detective who feel they were denied service by a Dunkin’ Donuts crew member,’ Bob Wiggins, a regional vice president, said in the e-mail obtained by The Post.


Online Options Trading #online #options #trading,trading #stock #options,stock #options #trading,how #to #trade #stock #options


#

Online Options Trading: find, open, and manage option trades in 10 minutes.

What’s the first thing that comes to mind when I say, “With online options trading you can find, execute, and manage multiple profitable options trades in less than 10 minutes?

Is it excitement, skepticism, utter disbelief? Are you now judging me without verifying, the claim?

For some people, that may sound a little too good to be true and that’s OK. The truth is, results speak louder than words!

Not only is it possible to find, execute and manage profitable trades in less than 10 minutes a day, but my students and I have been doing it with an extremely high success rate for years!

I designed the 10 minute strategy below as a proof of concept exercise. A simple low risk way for you to verify all the claims on this website.

Nothing is more powerful (and thrilling for me as a teacher) than a new student trying what they have learned in this course and seeing results almost instantly.

I’ve had great results using your blueprint. I’ve used it in ETF sector option using TT. ETF sectors are a great way to use options leverage to buy at a discount. The blueprint has worked good in the internet portfolio. Options can be very rewarding if you wait for the right trade and don’t force it. I risked

$10,000. In less than 2 hours the position was worth

$20,000. I closed half to protect capital. Using today’s high and low for an example, the remaining position I’m riding for free was worth between $2,700-$30,600 today!

Clint H.
MarketClub Member since 12/21/14

Travis, thanks for all your input. I bought a call option on TJX (monthly) gained 200%. Thanks. God bless.

Joseph N.
MarketClub Member since 7/27/08

***WARNING***

I can’t promise you’ll succeed. No one can. It’s actually safe to assume you will fail. At least that way you won’t fall victim to extreme optimism.

The results shown in this course often make online options trading seem easy and it’s not!

There are more “crash and burn” options trading stories then there are “rags to riches”.

And although I understand that ultimately you want to learn how to earn extra income for yourself and your family…my job is to make sure you learn the right way.

So please do not practice the strategy below unless you fully understand Modules 1-5 (table of contents below).

The stock market isn’t going anywhere. If it takes you 6 years longer to become a millionaire then so what, you’re still a millionaire.

My recommendation is that you start from Module 1 Lesson 1: explain option trading and go back through the whole course. Grab a piece of paper, take notes, and fully understand the concepts.

Then come back here to paper trade this strategy…

Trading Stock Options.

The great thing about Online options trading is that you can make money whether the stock market is going up, down, or trending sideways.

This is vastly different than some of the traditional forms of investing where your hard earned dollars rise and fall with the overall stock market.

If you recall from Module 1 stock options are contracts that give you the right to buy or sell a stock. Not all stocks have listed options, but the ones that do have numerous options available. These options can be bought, sold, or traded.

Stock options are derivatives. They are derived or come from the existence of stocks. IBM stock options are created for IBM the stock.

Technically speaking, the term derivative refers to how the price of these contracts is derived from the price of the stock. Their value is dependent on the price of the stock it was created for.

Generally speaking, the option’s value will rise and fall in sync with the stock price.

One very important point to keep in mind is that stock options mirror the movement and quality of the company stock it represents.

If you trade the stock options of a crap company then those options won’t be worth a crap. Not many people will be trading them and they won’t have attractive price movement.

Good stocks have good options to trade.

You want to trade high quality options. In order to do this you have to pick good stocks.

How this intimidates most people, because there is no broker researching stocks for you and it’s not like they teach you how to find good stocks in school.

You have to do all the research and your success or failure falls squarely on your shoulders.

It’s entirely up to you to figure out…

  • What to trade?
  • When to trade?
  • And how much to risk on your trades?

The good news is I’ve spent over 15 years trading options and I’ve finally created what I feel is the absolutely best “proof of concepts exercise” for new traders.

I call it the 10 Minute Options Strategy.

Watch the video below for instructions on how to implement this.

The “10-10-10” Trading Strategy

Ten minutes to place the trade, ten minutes to manage the trade, and ten minutes to close out the trade.

I want to add value to your life without you paying me a dime.

The strategy below is a “proof of concept” exercise taught in the Option Profit Formula Success Academy.

Not everyone can afford the Success Academy so the training below allows you to:

  • Implement the 10 minute strategy.
  • And enroll with your profits.

Or you can simply stop there and never join us. Either way I’m happy as I found a way to add value to your life.

So take a moment to test drive the strategy below. If you find value in the training then I hope to see you inside of our member’s area.

I don’t want to spend your money for you, but I do highly recommend you at least join Marketclub on a trial basis to practice this strategy.

Don’t let any “head trash” get in the way. Use your trading results to determine if you want this software in your bag of trading tricks (i.e. let the results speak for themselves ).

Personally, the reason I stay with them is because they have helped me earn several thousand dollars in profit over the years. And as a bonus the educational lessons they put out are good too.

However, if you are going to join Marketclub I suggest you wait until after you’ve watched the video so that you can maximize your trial period.

P.S. The link to your trial is here:

Message from Trader Travis: I don’t know what has brought you to my page. Maybe you are interested in options to help you reduce the risk of your other stock market holdings.

Maybe you are looking for a way to generate a little additional income for retirement. Or maybe you’ve just heard about options, you’re not sure what they are, and you want a simple step-by-step guide to understanding them and getting started with them.

I have no idea if options are even right for you, but I do promise to show you what has worked for me and the exact steps I’ve taken to use them to earn additional income, protect my investments, and to experience freedom in my life.

Just enter your best email below to claim my FREE report: Five Option Trading Strategies I’ve Used to Profit In Up, Down, and Sideways Markets.

Along with your FREE report, you’ll also get my daily emails where I share my favorite option trading strategies, examples of the trades I’m currently in, and ways to protect your investments in any market .

Products Created by Trader Travis

Free Options Course Learning Modules


Karachi Stock Exchange, PSX, KSE Market Anylsis, Tips, Reviews, buy stock.#Buy #stock


#

Karachi Stock Exchange, PSX, KSE Market Anylsis, Tips, Reviews

Karachi Stock Exchange, Paksitan Stock Exchange, PSX, KSE 100 Index, KSE 30 Index, Shares Information, Weekly Analysis and News, Board Meetings and Notices, Companies Results, Announcements and Earnings, Investment Tips, Stock Market, Share Prices and Trading

Buy stock

Buy stock

Pakistan Stock Exchange (PSX) Weekly Analysis 4 Sep, 2017

  • Volumes were bone dry across the board as investors were weary of market conditions and opted to stay on the side lines ahead of the long weekend
  • Foreigners’ net selling stood at USD8.8mn during the first three days of the week while Companies and Banks/DFIs absorbed the selling with net buying of USD10.5mn and USD3.6mn, respectively
  • Government has raised Petrol price by Rs2/ltr to Rs71.5/ltr from 1st Sep, Diesel price remains unchanged at Rs77.4/ltr
  • Pakistan s population soaring to 208mn in latest census
  • As monsoon rains continue to lash the city, the Karachi administration has requested Pakistan Army for assistance in conduct of rescue and relief activities in the city. Karachi administration requested army for assistance in managing torrential rain effect in city, the Inter-Services Public Relations (ISPR) said
  • The new spell of rains in Sindh will affect phutti (seed cotton) quality as excess moisture directly impacts cotton. Ginning factories refuse to buy cotton that contains moisture. It s not just cotton. There are onion, paddy and sugarcane crops that can face serious damages if heavy rain continues, said Mahmood Nawaz Shah, a cotton grower and vice president of SAB. He said the current rainfall has already caused a 50pc loss to the remainder of the crop that is ready to be harvested. Accumulation of rainwater is largely due to drainage that fails to work in heavy rain
  • Foreigners’ net selling stood at USD8.8mn during the first three days of the week while Companies and Banks/DFIs absorbed the selling with net buying of USD10.5mn and USD3.6mn, respectively
  • Government has raised Petrol price by Rs2/ltr to Rs71.5/ltr from 1st Sep, Diesel price remains unchanged at Rs77.4/ltr
  • Pakistan s population soaring to 208mn in latest census
  • As monsoon rains continue to lash the city, the Karachi administration has requested Pakistan Army for assistance in conduct of rescue and relief activities in the city. Karachi administration requested army for assistance in managing torrential rain effect in city, the Inter-Services Public Relations (ISPR) said
  • GoP s decision to sell its remaining stake in MARI through an SPO, proved to be a hefty blow for the stock as it pared gains made in recent days
  • The result season did not witness any major results during the outgoing week, which also played its part in evaporation of volumes from the market
  • The release of fertilize statistics proved to be a dampener for the sector amid lower urea sales on account of higher base seen last month, while on the DAP front EFERT managed to take a lead ahead of FFBL
  • Cement off-take registered a notable spike which helped the sector salvage some pride in the face of recent hammering driven by rumors of the pricing arrangement being derailed
  • Foreigners remained net sellers at the local index as FIPI recorded a MTD outflow of USD74.76mn while the eventful week saw a sum of USD8.74mn being traced outwards, especially in banking names. The remaining results season especially in oils and cements may bring some volumes, bringing a halt to the ongoing lull
  • The government is likely to import Liquefied Natural Gas (LNG) and POL products from Maldives after an Inter-Governmental Agreement (IGA) is inked between the two countries
  • Profits and dividends on foreign direct investment (FDI) repatriated in July amounted to $142 million compared to $125m in the same month of last fiscal year, the central bank reported on Friday
  • Puma Energy, a Singapore-based midstream and downstream oil firm, acquired a majority stake in oil marketing company Admore Gas Pvt Ltd to roll out its products in the country with growing gasoline consumption
  • Shares of Habib Bank Ltd (HBL) hit their lower lock on Monday as news of a possible fine of up to $630 million broke in the morning. The bank informed its shareholders about the development through a letter to the Pakistan Stock Exchange (PSX). It also announced the closure of its New York branch after receiving notice from the New York Department of Financial Services (DFS)
  • Amreli Steels Ltd informed the Pakistan Stock Exchange (PSX) on Monday about the second phase of its expansion plan and its current status. Its board approved the second phase of the expansion plan on April 20
  • The mobile phone imports surged by 48.41 per cent to $68.57 million during the first month of this fiscal year compared to $46.20m last in July 2016, according to the data of Pakistan Bureau of Statistics (PBS)
  • Edotco Group in partnership with Dawood Hercules Corporation Ltd (DH Corp) announced the acquisition of approximately 13,000 towers from Pakistan Mobile Communications Limited (Jazz)
  • Ali Jahangir Siddiqui has been appointed as Special Assistant to the Prime Minister with the status of Minister of State

Following are few BUY recommendations:


Pharmaceuticals Stock Price, Share Price, Live BSE #eusa #pharma

#pharma stocks

#

Pharmaceuticals

Indian Pharma sector has made rapid strides in both global and domestic market. But the growth pangs were severe for domestic players eyeing greater share of global pie. The slow down in generic approvals by USFDA, the payment problems witnessed in a few developing markets since the quarter ended December 2008 and accelerated genericisation and intense compe. more

Indian Pharma sector has made rapid strides in both global and domestic market. But the growth pangs were severe for domestic players eyeing greater share of global pie. The slow down in generic approvals by USFDA, the payment problems witnessed in a few developing markets since the quarter ended December 2008 and accelerated genericisation and intense competition together meant slower growth in global revenues for the domestic players. But despite challenging environment, the domestic players continued their consolidation mode and are getting ready for increased CRAMS business from the global majors. Attracted by enticing business model of the domestic pharma companies, some global players have acquired Indian pharma companies including Ranbaxy Laboratories, Matrix Laboratories etc. Simultaneously, we also witnessed global majors like Pfizer entering deal with domestic players like Aurobindo Pharma and Claris Lifesciences (unlisted) for marketing their generics in the advanced markets. Likewise, we are also witnessing increase in buy back / open offer for share holders of associates / subsidiaries of the MNC pharma companies. So, the pharma sector is in thick of action. With availability of skilled labour at low cost, India has become favorable destination for most of Multinational companies to manufacture their products and to develop new molecules. Consolidation has started in the Global Pharmaceutical industry with some mega merger proposals like Pfizer acquiring Wyeth, Merck & Co �Plough deal followed by Roche-Genetech deal etc. With many blockbuster drugs about to expire in the next 3-5 years and at the same time fall in the research pipeline has become major concern for the all MNC players. To maintain bottom-line, the top MNC companies are looking towards buying the generic players or partnership with generic player to market generic drugs in advanced markets. With huge cash in hand and attractive valuation, MNCs are also acquiring the majority stake in its emerging market subsidiaries in regular, India in particular. The MNC companies Novartis, Pfizer and Merck came with buy back proposal to acquire stake in their Indian Subsidiary. hide

updates





Aurobindo Pharma Ltd stock quote, Aurobindo Pharma Ltd company overview #pharmaceutical #companies #in #houston #tx

#aurobindo pharma

#

Aurobindo Pharma Ltd (ARBN.NS)

Indian shares closed slightly higher on Wednesday, led by drug maker Aurobindo Pharma Ltd after stellar quarterly results, but sentiment remained edgy as investors awaited further cues on whether the U.S. Federal Reserve will raise interest rates this year.

Aug 24 Indian shares closed slightly higher on Wednesday, led by drug maker Aurobindo Pharma Ltd after stellar quarterly results, but sentiment remained edgy as investors awaited further cues on whether the U.S. Federal Reserve will raise interest rates this year.

Aug 24 Indian shares crept up on Wednesday, led by drug maker Aurobindo Pharma Ltd after stellar quarterly results, but sentiment remained edgy as investors awaited further clues on whether the Federal Reserve will raise U.S. interest rates this year.

– Note: Reuters has not verified this story and does not vouch for its accuracy

** Shares of India’s pharmaceutical companies rise, with the Nifty Pharma Index gaining as much as 1.13 pct, its biggest in nearly four months

MUMBAI Aurobindo Pharma Ltd. India’s fourth-largest drugmaker by sales, said higher sales in the United States and emerging markets helped its fourth-quarter net profit grow 40 percent, above estimates, sending shares up as much as 4 percent.

MUMBAI, May 31 Aurobindo Pharma Ltd, India’s fourth-largest drugmaker by sales, said higher sales in the United States and emerging markets helped its fourth-quarter net profit grow 40 percent, above estimates, sending shares up as much as 4 percent.

** India’s Aurobindo Pharma gains as much as 5.1 pct, highest since Feb. 1, on U.S. FDA approval for its epilepsy prevention drug lacosamide

Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world’s largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Learn more about Thomson Reuters products:

Information, analytics and exclusive news on financial markets – delivered in an intuitive desktop and mobile interface

Everything you need to empower your workflow and enhance your enterprise data management

Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks

Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology

The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs

The industry leader for online information for tax, accounting and finance professionals





Stock: Teva Pharmaceutical Industries (TEVA) #avema #pharma #solutions

#barr pharma

#

Teva Pharmaceutical Industries (TEVA)

This article refers to the pharmaceutical company. For the Brazial real (BRL), see Brazilian Real (BRL) .

Barr Pharmaceuticals (formerly BRL) was the parent company for Barr Laboratories and Duramed Pharmaceuticals, Inc. before being acquired by Teva Pharmaceutical Industries (TEVA). Through its two subsidiaries the company produces roughly 75 different generic pharmaceuticals and 19 brand name pharmaceutical products, largely focused on women’s health and birth control.

On July 18th 2008, generic drug manufacturer Teva Pharmaceutical Industries (TEVA) announced it would buy Barr for $66.50 / share in cash and stock. Under the terms of the deal, each share of Barr common stock will be converted into $39.90 in cash and 0.6272 Teva American depositary receipts. Teva said it expects the deal to close in late 2008. [1]

Barr differentiates itself from the competitors in that it only seeks to formulate hard to reproduce brand name drugs, those with complex formulations or difficult to source materials. This strategy provides it with some measure of protection, by making it more difficult for other generics companies to replicate its products. The company may also benefit from overall growth in the generics market as Medicare and private insurance become increasingly receptive to generics, in the face of rising health care costs.

Contents

Business Financials

Barr makes most of its money from sales of generic products. Its sales of $1.3 billion in 2006 were about 75% from generic products and only 25% proprietary medications. As a subset of these areas, Barr’s most important therapeutic area is contraceptives and birth control. The striking difference between revenue and profits (net earnings) in the graphs could in part be caused by Barr’s increased marketing efforts of proprietary products in 2003-2004. Initial costs for marketing a product are very high, and as the patient base expands, these costs decrease meaning profits can increase.

An interesting strategy Barr employs is filing patent challenges first. If the challenge is successful, the company that filed the challenge receives 180 days of “exclusivity” wherein there is no competition from other generic producers.

Error creating thumbnail

Barr Annual Report [2]

Error creating thumbnail

Barr Annual Report [3]

Key Trends and Forces

*Towards Generic Drugs: The generic market has grown significantly in recent years. The percentage of overall prescriptions filled with generic products grew from 46.5% in 2000 to 57.3% by 2005 [4]. The aging population. rising health care costs, and insurance companies’ attempts to minimize costs could all contribute to a further increase in demand for generic products. Medicare spending could also play a significant role in the continued growth of the generics industry. The program which accounts for approx. 12% of the federal budget has been under pressure to cut costs. If Medicare moves to encourage greater use of generics, it would be a huge win for the industry and companies like BARR.

*Patent Expiration: Because Barr’s main focus is on generic drugs, one of the most important factors in determining its profitability are patent expirations of other companies’ successful medications. Pharmaceutical patents are generally short, and the process for gaining FDA Approval for a generic drug is much less rigorous than for a new medication. Often, generic manufacturers only have to prove that their product is equivalent. They do not have to go through the lengthy and expensive process of clinical trials.

When patents expire, often companies will attempt to reformulate products to maintain the patents. By adding new ingredients or changing the formula slightly, patent life can be extended, or brand domination can be maintained through the new formula. Thus, even if it appears that a patent will expire, there is no guarantee that this will really open up the market for generic manufacturers.

Error creating thumbnail

Barr Annual Report [5]

*Legal Challenges: Part of being a generic manufacturer means dealing with the “edge” of patents. That is, there is likely a gray area between when a product is protected by patent and when it is not. Because of this, companies such as Barr often face law suits from brand manufacturers. Currently, Barr has been fighting over patents on Yasmin, Ortho, Try-Cyclen Lo, and Allegra-D, which seem to be coming to an end soon.

*Brand Loyalty: Because patent laws allow brand name medications to monopolize the market for a certain number of years, brands have a chance to build loyalty and get people “hooked.” For example, if a patient is taking medication for a life-threatening condition, such as heart disease, doctors are unlikely to switch the patient to a new medication.

*Contraceptive Products: The market for contraceptives is especially important to Barr. One of its major products, the “morning after pill” called Plan-B, is very controversial in some areas. The product causes a fertilized egg not to implant itself in the uterus, and many claim that this is essentially a type of “pre-abortion.” Thus, legislation effecting abortion, as well as pharmacists’ ability to refuse to fill prescriptions, will effect sales of Plan-B. Also, there is constantly new research on side effects of oral contraceptives and hormones. If it is found that there are negative effects, Barr’s sales could suffer.

Competition

Because patent expiration means that any company can now access the formula of a medication and manufacture it, competition is fierce. Barr has a unique way of side-stepping some competition. It relies on four “qualifications” in deciding what products to produce. These include:

  1. Those with complex formulation or development characteristics;
  2. Those requiring specialized manufacturing capabilities;
  3. Those where sourcing the raw material may be difficult;
  4. Those that must overcome unusual regulatory or legal challenges, including patent challenges.

These conditions are designed to create generics that other companies cannot easily create. Barr goes after the more difficult products to manufacture, meaning that it will face less competition than if it went after easy products.

Error creating thumbnail

Company Annual Reports [6]

Barr’s major competitors including are:

  • Teva Pharmaceutical Industries (TEVA). Teva Pharmaceuticals USA is one if the largest producers of generic drugs. Its products include therapeutic areas such as anti-infective, cardiovascular, oncology, dermatological and anti-inflammatory.
  • Sandoz, a generic division of Novartis AG (NVS). Sandoz’s major therapeutic areas include antibiotics, preparations for treating the central nervous system, cardiovascular, hormones and antiallergics.
  • Mylan Laboratories (MYL) is the third largest generic producer in the US. Mylan also owns subsidiaries that produce proprietary drugs and hospital packages.
  • Dr. Reddy’s Laboratories (RDY) is one of the largest generic manufactures in the US by revenue. It also manufactures branded products. Dr. Reddy’s products include those for hypertension, allergies, urological disorders, cardiovascular, and antibiotics.

Notes





Endo Pharma’s stock logs its largest one-day loss in 14 years #ims #pharma

#endo pharma

#

Endo Pharma’s stock logs its largest one-day loss in 14 years

Shares of Endo Pharmaceuticals plunged in heavy trade Friday, as they suffered their worst one-day decline in 14 years on the heels of a disappointing outlook for profit and sales.

The Dublin, Ireland-based drugmaker’s stock ENDP, -2.03% tumbled 39% to the lowest close at the lowest level since May 29, 2009. That’s the third-biggest percentage selloff since the company went public in September 1996, behind the 46% drop on June, 24, 2002 and the 59% crash on Aug. 3, 1999. The rout shaved about $2.3 billion off the company’s market valuation.

Volume shot up to 57.8 million shares, which was nearly eight times the full-day average over the past 30 days, according to FactSet.

The stock was the biggest decliner in the S P 500, and the most active on the Nasdaq exchange, according to FactSet data.

The company said late Thursday that it expects full-year 2016 adjusted earnings per share of $4.50 to $4.80, below the FactSet consensus analyst estimate of $5.68. Revenue was projected to be $3.87 billion to $4.03 billion, compared with the FactSet consensus of $4.3 billion. That trumped better-than-expected first-quarter earnings and revenue .

The company blamed its disappointing outlook on new “unanticipated” competition, greater-than-expected price declines across the generics sector and delays on regulatory actions related to certain products.

Endo also said Brian Lortie, president of its U.S.-branded pharmaceuticals business, decided to step down, after seven years with the company.

Analyst Jason Gerberry at Leerink Partners cut his rating on the stock to market perform, after maintaining an outperform rating for at least the past three years. The analyst said he found it “increasingly difficult” to be constructive on any of the company’s sales-growth drivers. He slashed his stock price target to $23 from $37.

“We are lowering our rating…based on the revised business outlook, limited near-term catalysts and out lack of conviction that the [management] team can turnaround the business in a timely fashion,” Gerberry wrote in a Friday note to clients.

Copyright 2016 MarketWatch, Inc. All rights reserved.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. Intraday data delayed per exchange requirements. S P/Dow Jones Indices (SM) from Dow Jones Company, Inc. All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More information on NASDAQ traded symbols and their current financial status. Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S P/Dow Jones Indices (SM) from Dow Jones Company, Inc. SEHK intraday data is provided by SIX Financial Information and is at least 60-minutes delayed. All quotes are in local exchange time.

Stocks

Columns

Authors

Topics

No results found

LatestNews





Why I Don’t Invest in Penny Stocks – Frugal Rules #invest #in #penny #stocks, #penny


#

This post may contain affiliate links. Please read my disclosure page for more info.

We’ve all seen the ads that promise returns of 100-1000% or claim that buying penny stocks will make you rich. My principle regarding investing ads is simple if it sounds too good to be true, it is. While no one expects to lose money on an investment, we all need to be realistic. Unfortunately many of these ads prey on our naivety and make us think our pot of gold is just around the corner through their penny stock. There are varying definitions of what a penny stock is, but what I am focused on here are stocks not listed on any major exchange and under $1.

Information is King

Whenever I am ready to make a major purchase, I look for as much information as possible. I research, looking for what best fits my needs and then use that information to make my decision. I do not take this research lightly as I am looking to part with a large sum of cash and want to make a wise decision. I use this same mentality investing in the stock market.

I am a self-directed investor and when considering a stock purchase I spend considerable time (probably too much if you ask my wife) amassing any information I can find. Publicly-traded companies are required to publish loads of information, so it’s easy to come by. These requirements are non-existent for companies not listed on any of the major exchanges (such as those issuing penny stocks) and thus make it more difficult to come to a well-informed decision. I like to use screeners, like throse available through brokerages like Etrade or Optionshouse to help me make my investing decisions as they take a lot of this information and pare it down to justifiable options for me.

Related: If you re looking for a new online brokerage option, then check out my Scottrade review .

High Risk With Little Reward

We all have varying degrees of risk aversion . I tend to be on the risk-seeking end as I am willing to give up some risk to get the possibility of reward. The problem with many penny stocks is that there is very little upside potential. Sure, if you go from a share price of $.005 to $.01 you have doubled your money, but the reverse is also true.

You Can Lose Your Shirt

In theory any stock can go to $0 at any time. That is a risk we all assume when we put our money into the stock market . However, the risk is heightened when you go into penny stocks. Many times these stocks are near bankruptcy or have some other significant issue going on. This can make it extremely difficult to control losses or even get out of your investment if the company is going belly up.

Cheap Does Not Mean Good

My Dad had a saying growing up “Look for quality, not quantity.” This saying can easily be applied to investing when making a stock purchase. Would I rather buy 100,000 shares of a stock trading at $.01, or 100 shares of a stock trading $10? I am going to take the second option every time. Just because you can buy more does not mean it’s better.

Penny Stocks Can Be Hard to Sell

An inherent risk with penny stocks is that it can be difficult to get rid of them. Sporadic and irregular trading activity can cause you to lower your selling price to detrimental levels. As an aside, this can also breed manipulation of the price by some.

If it’s Too Good to be True, Then It’s Too Good to be True

Some promoters of penny stocks claim to peddle the next Google or Microsoft. Would I love to get it on a stock like that, sure I would! But, those stocks did not start out as penny stocks; they started on a major exchange. The rule of thumb to stick to is that if it sounds too good to be true, then it’s too good to be true.

This is not meant to say that it’s impossible to find success in penny stock investing, as it has happened. The problem is that the likelihood of finding success is so minimal that it’s not worth the risk. If you do choose to invest in penny stocks, please make sure and do your homework (as you would with any investment) before putting your hard earned money into it.

What questions do you have about penny stocks?

Archives

In accordance with FTC guidelines, Frugal Rules would like to disclose that it has financial arrangements with some of the entities mentioned herein. Frugal Rules may be compensated if visitors choose to click on some of the links located throughout the content on this site. Frugal Rules is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.

Copyright © 2012-2017 Frugal Rules. Ink Harmony, LLC | All Rights Reserved • design by Chip Thompson


FLKS stock quote – Flex Pharma, Inc #pharmaceutical #recruitment #agencies

#pharma stocks

#

Flex Pharma, Inc. Quote & Summary Data

Company Description (as filed with the SEC)

We are a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise-associated muscle cramps. Our product candidates are based on the potential mechanism of action we describe as Chemical Neuro Stimulation, which is the process by which a small molecule chemical signal, acting topically, induces a neuronal sensory signal that produces a beneficial effect. Our product candidates activate certain receptors in primary sensory neurons, which then act via neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. We believe that we are the only company developing both drug and consumer products based on this mechanism of muscle cramp inhibition. More.

Risk Grade

Where does FLKS fit in the risk graph?

Consensus Recommendation

Additional Info

Analyst Info

Research Brokers before you trade

Want to trade FX?

Edit Favorites

Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.

Customize your NASDAQ.com experience

Background Color Selector
Select the background color of your choice:

Quote Search
Select a default target page for your quote search:

Real-Time
After Hours
Pre-Market
News

Flash Quote
Summary Quote
Interactive Charts
Default Setting

Please note that once you make your selection, it will apply to all future visits to NASDAQ.com. If, at any time, you are interested in reverting to our default settings, please select Default Setting above.

Please confirm your selection:

You have selected to change your default setting for the Quote Search. This will now be your default target page; unless you change your configuration again, or you delete your cookies. Are you sure you want to change your settings?

We have a favor to ask

Please disable your ad blocker (or update your settings to ensure that javascript and cookies are enabled), so that we can continue to provide you with the first-rate market news and data you’ve come to expect from us.





Pharmaceuticals Stock Price, Share Price, Live BSE #pharmaceutical #packaging

#pharma stocks

#

Pharmaceuticals

Indian Pharma sector has made rapid strides in both global and domestic market. But the growth pangs were severe for domestic players eyeing greater share of global pie. The slow down in generic approvals by USFDA, the payment problems witnessed in a few developing markets since the quarter ended December 2008 and accelerated genericisation and intense compe. more

Indian Pharma sector has made rapid strides in both global and domestic market. But the growth pangs were severe for domestic players eyeing greater share of global pie. The slow down in generic approvals by USFDA, the payment problems witnessed in a few developing markets since the quarter ended December 2008 and accelerated genericisation and intense competition together meant slower growth in global revenues for the domestic players. But despite challenging environment, the domestic players continued their consolidation mode and are getting ready for increased CRAMS business from the global majors. Attracted by enticing business model of the domestic pharma companies, some global players have acquired Indian pharma companies including Ranbaxy Laboratories, Matrix Laboratories etc. Simultaneously, we also witnessed global majors like Pfizer entering deal with domestic players like Aurobindo Pharma and Claris Lifesciences (unlisted) for marketing their generics in the advanced markets. Likewise, we are also witnessing increase in buy back / open offer for share holders of associates / subsidiaries of the MNC pharma companies. So, the pharma sector is in thick of action. With availability of skilled labour at low cost, India has become favorable destination for most of Multinational companies to manufacture their products and to develop new molecules. Consolidation has started in the Global Pharmaceutical industry with some mega merger proposals like Pfizer acquiring Wyeth, Merck & Co �Plough deal followed by Roche-Genetech deal etc. With many blockbuster drugs about to expire in the next 3-5 years and at the same time fall in the research pipeline has become major concern for the all MNC players. To maintain bottom-line, the top MNC companies are looking towards buying the generic players or partnership with generic player to market generic drugs in advanced markets. With huge cash in hand and attractive valuation, MNCs are also acquiring the majority stake in its emerging market subsidiaries in regular, India in particular. The MNC companies Novartis, Pfizer and Merck came with buy back proposal to acquire stake in their Indian Subsidiary. hide

updates





Stock broker terms #stock #broker #terms


#

Stockbroker

BREAKING DOWN ‘Stockbroker’

It used to be that only the wealthy could afford hiring a broker to have access to the stock market. However, advances in technology, such as the Internet, gave rise to discount brokers that allowed small investors to trade the stock markets at a small fee. Because of discount brokers, nearly anybody can afford to invest in the stock market, even individuals who are based overseas. One downside to this is the lack of personalized service only a dedicated stockbroker can offer.

Educational Requirements

A bachelor’s degree in finance or business administration is typically required for stockbrokers. A deep understanding of financial laws and regulations, accounting methods. principles of economics and currency, financial planning and financial forecasting are necessary to ensure success in the field.

Various Country Licensing Requirements

Different countries have different requirements for stockbrokers. In Canada, would-be stockbrokers should be currently employed by a brokerage firm and are required to complete the Canadian Securities Course (CSC), Conduct and Practices Handbook (CPH) and the 90-day Investment Advisor Training Program (IATP). In Hong Kong, applicants have to be working for a licensed brokerage firm and pass three exams with the Hong Kong Securities Institute (HKSI). However, passing all three exams does not guarantee a license as it still has to be approved by the financial regulatory body.

In Singapore, becoming a trading representative requires passing four exams, Modules 1A, 5, 6 and 6A, administered by the Institute of Banking and Finance. A license is applied through the Monetary Authority of Singapore (MAS) and Singapore Exchange (SGX). In the United Kingdom, stockbroking is heavily regulated and brokers must achieve qualifications from the Financial Conduct Authority (FCA). The qualifications required depend on the duties required of the broker as well as his employer. In the United States, the designation “Registered Representative” is obtained by passing the General Securities Representative Exam, also known as the “Series 7 exam,” offered by the Financial Industry Regulatory Authority (FINRA). Applicants must also be employed with a registered brokerage firm.


HZNP Stock Price & News – Horizon Pharma PLC – Wall Street Journal #pharmaceutical #sales

#horizon pharma

#

Horizon Pharma PLC HZNP (U.S. Nasdaq)

P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock’s most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period. Earnings Per Share (TTM) A company’s net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock’s price. For companies with multiple common share classes, market capitalization includes both classes. Shares Outstanding Number of shares that are currently held by investors, including restricted shares owned by the company’s officers and insiders as well as those held by the public. Public Float The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded. Dividend Yield A company’s dividend expressed as a percentage of its current stock price.

Key Stock Data

P/E Ratio (TTM)
EPS (TTM)
Market Cap
Shares Outstanding
Public Float
Yield

HZNP has not issued dividends in more than 1 year.

Latest Dividend
Ex-Dividend Date

Shares Sold Short The total number of shares of a security that have been sold short and not yet repurchased. Change from Last Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month. Percent of Float Total short positions relative to the number of shares available to trade.

Short Interest (08/15/16)

Shares Sold Short
Change from Last
Percent of Float

Money Flow Uptick/Downtick Ratio Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an “uptick” in price and the value of trades made on a “downtick” in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.

Stock Money Flow

Uptick/Downtick Trade Ratio

Real-time U.S. stock quotes reflect trades reported through Nasdaq only.

International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times.

Quote data, except U.S. stocks, provided by SIX Financial Information.

Data is provided “as is” for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

All of the mutual fund and ETF information contained in this display was supplied by Lipper, A Thomson Reuters Company, subject to the following: Copyright © Thomson Reuters. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Bond quotes are updated in real-time. Source: Tullett Prebon.

Currency quotes are updated in real-time. Source: Tullet Prebon.

Fundamental company data and analyst estimates provided by FactSet. Copyright FactSet Research Systems Inc. All rights reserved.





FLKS stock quote – Flex Pharma, Inc #pharmajobs

#pharma stocks

#

Flex Pharma, Inc. Quote & Summary Data

Company Description (as filed with the SEC)

We are a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise-associated muscle cramps. Our product candidates are based on the potential mechanism of action we describe as Chemical Neuro Stimulation, which is the process by which a small molecule chemical signal, acting topically, induces a neuronal sensory signal that produces a beneficial effect. Our product candidates activate certain receptors in primary sensory neurons, which then act via neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. We believe that we are the only company developing both drug and consumer products based on this mechanism of muscle cramp inhibition. More.

Risk Grade

Where does FLKS fit in the risk graph?

Consensus Recommendation

Additional Info

Analyst Info

Research Brokers before you trade

Want to trade FX?

Edit Favorites

Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.

Customize your NASDAQ.com experience

Background Color Selector
Select the background color of your choice:

Quote Search
Select a default target page for your quote search:

Real-Time
After Hours
Pre-Market
News

Flash Quote
Summary Quote
Interactive Charts
Default Setting

Please note that once you make your selection, it will apply to all future visits to NASDAQ.com. If, at any time, you are interested in reverting to our default settings, please select Default Setting above.

Please confirm your selection:

You have selected to change your default setting for the Quote Search. This will now be your default target page; unless you change your configuration again, or you delete your cookies. Are you sure you want to change your settings?

We have a favor to ask

Please disable your ad blocker (or update your settings to ensure that javascript and cookies are enabled), so that we can continue to provide you with the first-rate market news and data you’ve come to expect from us.





Pharmaceuticals Stock Price, Share Price, Live BSE #world-pharma.org

#pharma stocks

#

Pharmaceuticals

Indian Pharma sector has made rapid strides in both global and domestic market. But the growth pangs were severe for domestic players eyeing greater share of global pie. The slow down in generic approvals by USFDA, the payment problems witnessed in a few developing markets since the quarter ended December 2008 and accelerated genericisation and intense compe. more

Indian Pharma sector has made rapid strides in both global and domestic market. But the growth pangs were severe for domestic players eyeing greater share of global pie. The slow down in generic approvals by USFDA, the payment problems witnessed in a few developing markets since the quarter ended December 2008 and accelerated genericisation and intense competition together meant slower growth in global revenues for the domestic players. But despite challenging environment, the domestic players continued their consolidation mode and are getting ready for increased CRAMS business from the global majors. Attracted by enticing business model of the domestic pharma companies, some global players have acquired Indian pharma companies including Ranbaxy Laboratories, Matrix Laboratories etc. Simultaneously, we also witnessed global majors like Pfizer entering deal with domestic players like Aurobindo Pharma and Claris Lifesciences (unlisted) for marketing their generics in the advanced markets. Likewise, we are also witnessing increase in buy back / open offer for share holders of associates / subsidiaries of the MNC pharma companies. So, the pharma sector is in thick of action. With availability of skilled labour at low cost, India has become favorable destination for most of Multinational companies to manufacture their products and to develop new molecules. Consolidation has started in the Global Pharmaceutical industry with some mega merger proposals like Pfizer acquiring Wyeth, Merck & Co �Plough deal followed by Roche-Genetech deal etc. With many blockbuster drugs about to expire in the next 3-5 years and at the same time fall in the research pipeline has become major concern for the all MNC players. To maintain bottom-line, the top MNC companies are looking towards buying the generic players or partnership with generic player to market generic drugs in advanced markets. With huge cash in hand and attractive valuation, MNCs are also acquiring the majority stake in its emerging market subsidiaries in regular, India in particular. The MNC companies Novartis, Pfizer and Merck came with buy back proposal to acquire stake in their Indian Subsidiary. hide

updates





FLKS stock quote – Flex Pharma, Inc #small #pharma #companies

#pharma stocks

#

Flex Pharma, Inc. Quote & Summary Data

Company Description (as filed with the SEC)

We are a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise-associated muscle cramps. Our product candidates are based on the potential mechanism of action we describe as Chemical Neuro Stimulation, which is the process by which a small molecule chemical signal, acting topically, induces a neuronal sensory signal that produces a beneficial effect. Our product candidates activate certain receptors in primary sensory neurons, which then act via neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. We believe that we are the only company developing both drug and consumer products based on this mechanism of muscle cramp inhibition. More.

Risk Grade

Where does FLKS fit in the risk graph?

Consensus Recommendation

Additional Info

Analyst Info

Research Brokers before you trade

Want to trade FX?

Edit Favorites

Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.

Customize your NASDAQ.com experience

Background Color Selector
Select the background color of your choice:

Quote Search
Select a default target page for your quote search:

Real-Time
After Hours
Pre-Market
News

Flash Quote
Summary Quote
Interactive Charts
Default Setting

Please note that once you make your selection, it will apply to all future visits to NASDAQ.com. If, at any time, you are interested in reverting to our default settings, please select Default Setting above.

Please confirm your selection:

You have selected to change your default setting for the Quote Search. This will now be your default target page; unless you change your configuration again, or you delete your cookies. Are you sure you want to change your settings?

We have a favor to ask

Please disable your ad blocker (or update your settings to ensure that javascript and cookies are enabled), so that we can continue to provide you with the first-rate market news and data you’ve come to expect from us.





Raptor Pharmaceutical (RPTP) Stock Slumps, Said to be Exploring Sale #pharmaceutics

#raptor pharma

#

Raptor Pharmaceutical (RPTP) Stock Slumps, Said to be Exploring Sale

NEW YORK (TheStreet ) — Shares of Raptor Pharmaceutical Corp. (RPTP ) are dipping by 5.85% to $5.47 on heavy trading volume Thursday afternoon, as the biopharmaceutical company is in talks with investment banks to hire a financial adviser to explore a possible sale, according to sources cited by Reuters after yesterday’s market close.

The move may not lead to a sale, the sources added.

JMP Securities upgraded the stock to “market outperform” from “market perform” and established a $9 price target following the report.

A sale of Raptor makes sense because it is almost a classic model for recent transactions where specialty pharma companies have purchased orphan disease companies, the firm said.

“Raptor has steady revenue from Procysbi, approved for cystinosis, and it will soon begin selling Quinsair, an antibiotic for cystic fibrosis in the EU and Canada. While the company could be quickly profitable on these assets alone, as an independent company, it must invest in R D to drive long-term growth, which is a drag on earnings,” JMP Securities wrote in a note.

A number of companies including Horizon Pharma (HZNP), Shire (SHPG) and Allergan (AGN) could be interested in the company, according to the firm.

Novato, CA-based Raptor is focused on developing and commercializing treatments for people affected by rare and debilitating diseases.

About 2.01 million of Raptor’s shares were traded by this afternoon compared to its average 30-day volume of 1.2 million shares per day.

Separately, TheStreet Ratings Team has a “Sell” rating with a score of D on the stock.

The company’s weaknesses can be seen in multiple areas, such as its weak operating cash flow and generally disappointing historical performance in the stock itself.





Steven Trax #financial #advisor, #financial #planner, #investments, #ria, #cfp, #registered #investment #advisor, #independent #financial #advisor,


#

Steven Trax Reston, Virginia

Steven Brent Trax is a financial advisor employed by MTX Wealth Management in Reston, Virginia. With over 21 years of experience and 1 exam passed, Steven maintains the following registrations:

Investment Advisor
Steven is registered with the SEC as an Investment Advisor, which is defined as someone who is paid to provide advice about securities. Investment advisors can also be paid to manage investment portfolios or offer financial planning services. Other terms commonly used for investment advisors include Investment Advisor Representative (IAR) and Registered Investment Advisor (RIA).

Broker
Mr. Trax is also registered with FINRA as a Broker (sometimes referred to as a broker-dealer registered rep. or RR ). Brokers are the sales personnel who work for larger brokerage firms. These firms (also known as broker-dealers ) are in the business of buying and selling securities such as stocks, bonds, mutual funds and other investment-related products. These firms are also registered with FINRA and can engage in securities transactions on behalf of its customers (as broker) or for its own account (as dealer).

Advisor data current as of May 15, 2017

Fees and Services

Advisory services offered:

  • Financial Planning
  • Portfolio Management for Individuals
  • Securities Portfolio Management
  • Selection of Other Advisors

State Registrations

Financial advisors must register with each state in which they conduct business. Below is a record of each state where Steven Trax maintains an active registration.

For those interested in managing some of your investments on your own we have more research tools that may be of assistance. Below is a sample list of funds from our Mutual Funds Research Topic. where you can sort and filter mutual funds based on annual performance, ratings, fees and much more. We also publish an up-to-date Online Brokers Research Topic which lists current promotions and a Smart Rating Score for each firm.

Mutual Funds Research Topic

Find Highest-Rated
Mutual Funds >>

Data updated on May 15, 2017 via the following sources:
SEC Investment Advisor Public Dislcosure: adviserinfo.sec.gov
FINRA BrokerCheck: brokercheck.finra.org


Raptor Pharmaceutical Stock Upgraded: 3 Things You Need to Know – The Motley Fool #surya

#raptor pharma

#

Raptor Pharmaceutical Stock Upgraded: 3 Things You Need to Know

Apr 7, 2016 at 1:15PM

Shares of small-cap orphan drug developer Raptor Pharmaceutical (NASDAQ:RPTP ) surged 24% in Wednesday trading, after Reuters reported that investment bankers have been brought on board to discuss a sale of the company.

Raptor has declined to comment on the rumors, however, and with Raptor stock now down 5% in Thursday morning trading, enthusiasm for the development may already be waning. But could it be that today’s 5% retracement is giving investors a chance to take a second bite at the apple on Raptor Pharmaceutical stock?

Here are three things you need to know to decide .

Thing No. 1: This deal would be a good deal (for Raptor)
Confirming Reuters’ report yesterday, analysts at Oppenheimer commented early this morning with comments that Raptor selling itself to an acquirer is a “good idea.” Oppenheimer believes that a deal could raise Raptor’s share price as high as $7 or $8 a share.

Raptor currently costs just $5 and change, the implication being that if the rumors are true, Raptor Pharmaceutical stock could soon be good for a 45% profit.

Thing No. 2: The rumors may be true
A second analyst, JMP Securities, has chimed in to suggest that any of Horizon Pharma (NASDAQ:HZNP ). Shire (NASDAQ:SHPG ). or even Allergan (NYSE:AGN ) could potentially be interested in acquiring Raptor.

According to the ratings watchers at TheFly.com. JMP is even more gung-ho for this deal than Oppenheimer. Not only does JMP assign a higher price target to Raptor stock — $9 per share — but it’s also enthusiastic enough about the deal that JMP is upgrading Raptor stock to buy (whereas Oppenheimer still has the stock at perform).

Thing No. 3: JMP’s likely suspects actually aren’t entirely unlikely
With Raptor stock currently selling for just $5 and change, the entire company is valued at a market capitalization of just $460 million. Posit a buyout price of $9 a share, and the entire company would cost at most $767 million. So how likely is it that any of the three firms JMP named as likely suitors could afford to buy Raptor Pharmaceutical?

Actually, pretty likely. The smallest of the firms named, Dublin-based Horizon Pharma, is 6 times Raptor’s size today, and has $860 million on its balance sheet — plenty of money to accomplish an all-cash buyout should Horizon be so inclined. Shire has less cash on hand, but at nearly $36 billion in market cap, Shire could conceivably make an all-stock bid for Raptor (or finance a buyout with debt). Allergan, meanwhile, is the biggest of the three firms named. With $96.5 billion in market capitalization and with $1.11 billion in the bank, Allergan could go either route, paying in cash or in stock.

The most important thing
The bigger question is whether any of these firms would want to own Raptor Pharmaceutical, which after all isn’t currently profitable. That’s not necessarily an obstacle, as Raptor has a decent pipeline of products in development, and an established business to boot, bringing in $94 million in annual revenue. But lack of profits would still be a disincentive to an acquirer. The valuation on the stock could be another.

At today’s 5.2 times sales valuation, Raptor is currently cheaper than either Shire (5.6 times sales) or Allergan (6.4 times sales). It’s more expensive than Horizon, however, which at 4 times sales would have to pay a very big premium to its own P/S ratio to acquire Raptor — and dilute its own profitable business with Raptor’s money-loser in the process. Accordingly, I’d say Horizon is probably the least likely of the three bidders JMP named to make a bid for Raptor.

That leaves Shire and Allergan — profitable, big businesses both — as the most likely suitors. Whether either one would want to own Raptor, however, remains anybody’s guess.

Fool contributorRich Smithdoes not own shares of, nor is he short, any company named above. You can find him onMotley Fool CAPS, publicly pontificating under the handleTMFDitty, where he’s currently ranked No. 290 out of more than 75,000 rated members.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .





Ajanta Pharma Ltd stock quote, Ajanta Pharma Ltd company overview #diamond #pharma

#ajanta pharma

#

Ajanta Pharma Ltd (AJPH.NS)

Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world’s largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Learn more about Thomson Reuters products:

Information, analytics and exclusive news on financial markets – delivered in an intuitive desktop and mobile interface

Everything you need to empower your workflow and enhance your enterprise data management

Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks

Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology

The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs

The industry leader for online information for tax, accounting and finance professionals





How to Buy and Sell Stocks Online #buying #stock #on #line


#

How to Buy and Sell Stocks Online

To a large degree, the days of calling up a broker to buy or sell stocks is gone. Discount stock brokerage firms all offer online account and trading access. To get started with buying and selling stocks online, you need to select a brokerage firm and open an account. The online systems make buying and selling easy — to generate more commissions for your broker. Your challenge is to develop an investing or trading strategy that will produce profits for your investment portfolio.

An online brokerage account allows you to buy and sell stocks from any computer.

credit: Jupiterimages/BananaStock/Getty Images

Step

Select an online broker. Do not base your broker selection on commission rates alone. SmartMoney magazine publishes — online — an annual survey and ranking of online discount brokers. The magazine looks at product offerings, research, trading tools and customer service as well as commission and fees. You should compare brokers using the same factors along with your personal investing goals.

Step

Determine which type of account you need. Brokers offer three main types of accounts — cash, margin and retirement. Retirement accounts are for tax-qualified individual retirement accounts — IRAs. A margin account allows you to borrow a portion of the cost of stocks. If you plan to be an active stock trader, you will need a margin account. A cash account would be appropriate if you want to start stock investing with a small amount of money or plan to buy and hold your share investments.

Step

Complete the broker s account application. The account application can be completed online through your selected broker s website. As part of the application process you will set up your online user name and password. Once the account is approved, you can log in to your account through the brokerage firm website.

Step

Fund your account. The broker s website will provide directions for sending money to fund your account. A wire transfer is the fastest method, but you will incur wire fees from your bank. If you set up an Automated Clearing House — ACH — transfer from your bank, the money will be in your brokerage account in a few days. The ACH setup will also allow you to withdraw money from your brokerage account to your bank account.

Step

Familiarize yourself with the broker s online tools. At a minimum you need to know how to look up stock prices, find the current values of your investments and which screens you use to place buy and sell orders. The trading and research tools provided on the broker s website can be used to help with the selection of stocks.

Step

Learn about the different types of stock market orders and when you would use each type. The trade screen for your online brokerage account allows you to enter different types of orders, including market, limit and stop orders. You can also control how long an order is open — for the current trading day only or good-til-canceled (GTC). A market order buys or sells at the current stock market prices. Limit and stop orders allow you to buy and sell when a stock s share price hits predetermined levels.


ALPMY Stock Price & News – Astellas Pharma Inc #pharma #trust

#astellas pharma

#

Astellas Pharma Inc. ADR ALPMY (U.S. OTC)

P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock’s most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period. Earnings Per Share (TTM) A company’s net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock’s price. For companies with multiple common share classes, market capitalization includes both classes. Shares Outstanding Number of shares that are currently held by investors, including restricted shares owned by the company’s officers and insiders as well as those held by the public. Public Float The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded. Dividend Yield A company’s dividend expressed as a percentage of its current stock price.

Key Stock Data

P/E Ratio (TTM)
EPS (TTM)
Market Cap
Shares Outstanding
Public Float
Yield

ALPMY has not issued dividends in more than 1 year.

Latest Dividend
Ex-Dividend Date

Shares Sold Short The total number of shares of a security that have been sold short and not yet repurchased. Change from Last Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month. Percent of Float Total short positions relative to the number of shares available to trade.

Short Interest ()

Money Flow Uptick/Downtick Ratio Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an “uptick” in price and the value of trades made on a “downtick” in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.

Stock Money Flow

Real-time U.S. stock quotes reflect trades reported through Nasdaq only.

International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times.

Quote data, except U.S. stocks, provided by SIX Financial Information.

Data is provided “as is” for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

All of the mutual fund and ETF information contained in this display was supplied by Lipper, A Thomson Reuters Company, subject to the following: Copyright © Thomson Reuters. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Bond quotes are updated in real-time. Source: Tullett Prebon.

Currency quotes are updated in real-time. Source: Tullet Prebon.

Fundamental company data and analyst estimates provided by FactSet. Copyright FactSet Research Systems Inc. All rights reserved.





SSYS Stock Price & News – Stratasys Ltd #stratasys #ltd. #stock #price, #stratasys #ltd. #stock


#

Stratasys Ltd. SSYS (U.S. Nasdaq)

P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock’s most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period. Earnings Per Share (TTM) A company’s net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock’s price. For companies with multiple common share classes, market capitalization includes both classes. Shares Outstanding Number of shares that are currently held by investors, including restricted shares owned by the company’s officers and insiders as well as those held by the public. Public Float The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded. Dividend Yield A company’s dividend expressed as a percentage of its current stock price.

Key Stock Data

P/E Ratio (TTM)
EPS (TTM)
Market Cap
Shares Outstanding
Public Float
Yield

SSYS has not issued dividends in more than 1 year.

Latest Dividend
Ex-Dividend Date

Shares Sold Short The total number of shares of a security that have been sold short and not yet repurchased. Change from Last Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month. Percent of Float Total short positions relative to the number of shares available to trade.

Short Interest (05/15/17)

Shares Sold Short
Change from Last
Percent of Float

Money Flow Uptick/Downtick Ratio Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an “uptick” in price and the value of trades made on a “downtick” in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.

Stock Money Flow

Uptick/Downtick Trade Ratio

Real-time U.S. stock quotes reflect trades reported through Nasdaq only.

International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times.

Quote data, except U.S. stocks, provided by SIX Financial Information.

Data is provided “as is” for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

All of the mutual fund and ETF information contained in this display was supplied by Lipper, A Thomson Reuters Company, subject to the following: Copyright © Thomson Reuters. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Bond quotes are updated in real-time. Source: Tullett Prebon.

Currency quotes are updated in real-time. Source: Tullet Prebon.

Fundamental company data and analyst estimates provided by FactSet. Copyright FactSet Research Systems Inc. All rights reserved.


The 5-Minute Guide to Horizon Pharma PLC Stock – The Motley Fool #jobs #pharmaceutical #industry

#horizon pharma

#

The 5-Minute Guide to Horizon Pharma PLC Stock

Value investors don’t need to know a mitochondria from a hole in the ground to sense something’s amiss with Horizon Pharmaceuticals (NASDAQ:HZNP ) stock. Over the past several years the company’s sales have exploded, yet the stock fallen roughly 50% from its peak last summer.

With a forward price-to-earnings ratio under 10, this looks like a bargain hunter’s dream come true. Before you go diving in, take five minutes to familiarize yourself with this company. You’ll be glad you did.

Pharma-funds
Even if you don’t follow pharmaceutical industry news, by now you’re probably familiar with “pharma-bro” Martin Shkreli. While CEO of Touring Pharmaceuticals he orchestrated an overnight 5,500% price hike of rare disease drug daraprim, and a media frenzy ensued.

While he took the practice to an extreme, his activity drew attention to an industry trend that had been taking place for years. Developing new drugs is risky, and as companies grow their returns on R D tend to shrink. Companies such as Valeant Pharmaceuticals. and Horizon Pharma, among others, realized that acquiring drugs that have already won approval, then unlocking their value through flawless execution of commercial strategy, is a viable business model. Imagine a fund manager able to purchase undervalued stocks, then set their prices as high as the market will bear on his own.

What some might call excessive price raising has led to unprecedented scrutiny of Valeant’s, as well as Horizon’s, relationships with certain specialty pharmaceutical distributors, and price raising practices. This scrutiny during an election year has devastated Valeant’s share price over the past several months, along with the SPDR S P Pharmaceuticals ETF (NYSEMKT:XPH ) of which Horizon Pharma is a top-ten holding.

Horizon Pharmaceuticals’ model isn’t identical to Valeant’s or Touring’s, but it isn’t terribly research heavy either. Since 2013, Horizon has increased its medicines portfolio from two products to nine, as of this January. The addition of those products sent Horizon’s sales through the roof, from just $18.8 million in 2012, to $757 million in 2015. Last year alone it began recognizing revenue from three recently acquired drugs — Pennsaid, Ravicti, and Buphenyl — adding $247.3 million its top line.

As its declining R D expense as a percentage of revenue shows, it didn’t develop those drugs itself. It acquired them, and ended 2015 with over $1.1 billion in debt. Last year it spent $69.9 million servicing those debts, and has some heavy contractual cash obligations in the years ahead. This year Horizon is on the hook for $92 million, and $74 million next year.

The $859.6 million in cash and equivalents on the books at the end of the 2015 might have helped its investors sleep easier. Following a $510 million acquisition of Crealta Holdings in January, much of the stuffing has fallen out of that pillow.

The products
Now that you know how Horizon leapfrogged into the big leagues, let’s look at some of the products. After all, their sales will be responsible for paying down those enormous debts, and hopefully generating some earnings. If you’re expecting some groundbreaking medical advances, you’re going to be disappointed. Last year, Horizon’s two best-selling products were combinations of drugs you can buy over-the-counter.

In first place was Duexis for relief of arthritic pain and prevention of gastric ulcers, which brought in $190 million, or 25% of Horizon’s total sales. It’s a combination of famotidine, which you’ll probably recognize by the brand name Pepcid, and ibuprofin.

Coming in second was Vimovo, also for relief of arthritic pain and ankylosing spondylitis, with sales of $166.7 million. It’s a combination of naproxen and esomeprazole magnesium, which you’ll probably recognize by their brand names, Aleve and Nexium.

Image source: Horizon Pharma PLC.

That’s right. Nearly half of the company’s revenue came from over the counter drugs combined into easy to administer pills. That convenience is expensive, and becoming more so. Pharmaceutical companies are not terribly forthcoming with pricing details, but recently the Centers for Medicare and Medicaid Services published some interesting information. In 2014, the annual change in average cost per unit of Vimovo rose 534% and cost Medicare Part D patients an average of $1,826 per beneficiary.

If you’re wondering why patients might be willing to shell out what must be a substantial co-pay, rather than swallow Pepsin or Nexium, before taking their ibuprofen or naproxen, let me introduce you to another standard practice in the pharmaceutical industry: Copay assistance programs. Out-of-pocket costs can be burdensome for patients, but with gross margins on pharmaceuticals so wide, companies are often willing “help” patients, then pocket enormous sums when the above-copay cost is covered by the insurance company.

Unwanted attention
Horizon Pharma’s extensive use of patient assistance programs, and relationships with specialty pharmacies hasn’t gone unnoticed by some authorities. Last November the company received a subpoena from the U.S. Attorney’s Office for the Southern District of New York requesting documents related to its patient assistance programs and other activities.

As bad as that may seem, the authorities may be the least of Horizon’s worries in the quarters ahead. America’s two largest pharmacy benefit managers Express Scripts. and CVS Health specifically exclude reimbursement for Duexis, and Vimovo, but some specialty pharmacies didn’t get the message. Express Scripts has been cracking down on specialty pharmacies that dispense formulary excluded drugs, and it will be interesting to see the effect on Horizon’s sales in the quarters ahead.

In transition
To be fair, Horizon’s more recent acquisitions, such as Krystexxa for treatment of gout in patients that no longer respond conventional therapy, look like an effort to reduce its dependance on aggressive price raising of drugs that aren’t terribly innovative. Also, a move to the low corporate tax haven of Ireland would do wonders to its bottom line. However, if sales of its top two drugs plummet there won’t be much profit to tax anyway.

Considering its debt pile however, transitioning to a company truly focused on innovation might be impossible. It will be fun to see what effect specialty pharma crackdowns and U.S. attorney investigations have on Horizon Pharma in the quarters ahead; from the sidelines, not as a shareholder.

Cory Renauer has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .





Pharmaceuticals Stock Price, Share Price, Live BSE #pharma #suite

#pharma stocks

#

Pharmaceuticals

Indian Pharma sector has made rapid strides in both global and domestic market. But the growth pangs were severe for domestic players eyeing greater share of global pie. The slow down in generic approvals by USFDA, the payment problems witnessed in a few developing markets since the quarter ended December 2008 and accelerated genericisation and intense compe. more

Indian Pharma sector has made rapid strides in both global and domestic market. But the growth pangs were severe for domestic players eyeing greater share of global pie. The slow down in generic approvals by USFDA, the payment problems witnessed in a few developing markets since the quarter ended December 2008 and accelerated genericisation and intense competition together meant slower growth in global revenues for the domestic players. But despite challenging environment, the domestic players continued their consolidation mode and are getting ready for increased CRAMS business from the global majors. Attracted by enticing business model of the domestic pharma companies, some global players have acquired Indian pharma companies including Ranbaxy Laboratories, Matrix Laboratories etc. Simultaneously, we also witnessed global majors like Pfizer entering deal with domestic players like Aurobindo Pharma and Claris Lifesciences (unlisted) for marketing their generics in the advanced markets. Likewise, we are also witnessing increase in buy back / open offer for share holders of associates / subsidiaries of the MNC pharma companies. So, the pharma sector is in thick of action. With availability of skilled labour at low cost, India has become favorable destination for most of Multinational companies to manufacture their products and to develop new molecules. Consolidation has started in the Global Pharmaceutical industry with some mega merger proposals like Pfizer acquiring Wyeth, Merck & Co �Plough deal followed by Roche-Genetech deal etc. With many blockbuster drugs about to expire in the next 3-5 years and at the same time fall in the research pipeline has become major concern for the all MNC players. To maintain bottom-line, the top MNC companies are looking towards buying the generic players or partnership with generic player to market generic drugs in advanced markets. With huge cash in hand and attractive valuation, MNCs are also acquiring the majority stake in its emerging market subsidiaries in regular, India in particular. The MNC companies Novartis, Pfizer and Merck came with buy back proposal to acquire stake in their Indian Subsidiary. hide

updates





Aurobindo Pharma Ltd stock quote, Aurobindo Pharma Ltd company overview #pharmaceutical #science

#aurobindo pharma

#

Aurobindo Pharma Ltd (ARBN.NS)

Indian shares closed slightly higher on Wednesday, led by drug maker Aurobindo Pharma Ltd after stellar quarterly results, but sentiment remained edgy as investors awaited further cues on whether the U.S. Federal Reserve will raise interest rates this year.

Aug 24 Indian shares closed slightly higher on Wednesday, led by drug maker Aurobindo Pharma Ltd after stellar quarterly results, but sentiment remained edgy as investors awaited further cues on whether the U.S. Federal Reserve will raise interest rates this year.

Aug 24 Indian shares crept up on Wednesday, led by drug maker Aurobindo Pharma Ltd after stellar quarterly results, but sentiment remained edgy as investors awaited further clues on whether the Federal Reserve will raise U.S. interest rates this year.

– Note: Reuters has not verified this story and does not vouch for its accuracy

** Shares of India’s pharmaceutical companies rise, with the Nifty Pharma Index gaining as much as 1.13 pct, its biggest in nearly four months

MUMBAI Aurobindo Pharma Ltd. India’s fourth-largest drugmaker by sales, said higher sales in the United States and emerging markets helped its fourth-quarter net profit grow 40 percent, above estimates, sending shares up as much as 4 percent.

MUMBAI, May 31 Aurobindo Pharma Ltd, India’s fourth-largest drugmaker by sales, said higher sales in the United States and emerging markets helped its fourth-quarter net profit grow 40 percent, above estimates, sending shares up as much as 4 percent.

** India’s Aurobindo Pharma gains as much as 5.1 pct, highest since Feb. 1, on U.S. FDA approval for its epilepsy prevention drug lacosamide

Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world’s largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Learn more about Thomson Reuters products:

Information, analytics and exclusive news on financial markets – delivered in an intuitive desktop and mobile interface

Everything you need to empower your workflow and enhance your enterprise data management

Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks

Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology

The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs

The industry leader for online information for tax, accounting and finance professionals





Ajanta Pharma Ltd stock quote, Ajanta Pharma Ltd company overview #uman #pharma

#ajanta pharma

#

Ajanta Pharma Ltd (AJPH.NS)

Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world’s largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Learn more about Thomson Reuters products:

Information, analytics and exclusive news on financial markets – delivered in an intuitive desktop and mobile interface

Everything you need to empower your workflow and enhance your enterprise data management

Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks

Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology

The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs

The industry leader for online information for tax, accounting and finance professionals





Endo Pharma’s stock logs its largest one-day loss in 14 years #hi #tech #pharma

#endo pharma

#

Endo Pharma’s stock logs its largest one-day loss in 14 years

Shares of Endo Pharmaceuticals plunged in heavy trade Friday, as they suffered their worst one-day decline in 14 years on the heels of a disappointing outlook for profit and sales.

The Dublin, Ireland-based drugmaker’s stock ENDP, -2.03% tumbled 39% to the lowest close at the lowest level since May 29, 2009. That’s the third-biggest percentage selloff since the company went public in September 1996, behind the 46% drop on June, 24, 2002 and the 59% crash on Aug. 3, 1999. The rout shaved about $2.3 billion off the company’s market valuation.

Volume shot up to 57.8 million shares, which was nearly eight times the full-day average over the past 30 days, according to FactSet.

The stock was the biggest decliner in the S P 500, and the most active on the Nasdaq exchange, according to FactSet data.

The company said late Thursday that it expects full-year 2016 adjusted earnings per share of $4.50 to $4.80, below the FactSet consensus analyst estimate of $5.68. Revenue was projected to be $3.87 billion to $4.03 billion, compared with the FactSet consensus of $4.3 billion. That trumped better-than-expected first-quarter earnings and revenue .

The company blamed its disappointing outlook on new “unanticipated” competition, greater-than-expected price declines across the generics sector and delays on regulatory actions related to certain products.

Endo also said Brian Lortie, president of its U.S.-branded pharmaceuticals business, decided to step down, after seven years with the company.

Analyst Jason Gerberry at Leerink Partners cut his rating on the stock to market perform, after maintaining an outperform rating for at least the past three years. The analyst said he found it “increasingly difficult” to be constructive on any of the company’s sales-growth drivers. He slashed his stock price target to $23 from $37.

“We are lowering our rating…based on the revised business outlook, limited near-term catalysts and out lack of conviction that the [management] team can turnaround the business in a timely fashion,” Gerberry wrote in a Friday note to clients.

Copyright 2016 MarketWatch, Inc. All rights reserved.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. Intraday data delayed per exchange requirements. S P/Dow Jones Indices (SM) from Dow Jones Company, Inc. All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More information on NASDAQ traded symbols and their current financial status. Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S P/Dow Jones Indices (SM) from Dow Jones Company, Inc. SEHK intraday data is provided by SIX Financial Information and is at least 60-minutes delayed. All quotes are in local exchange time.

Stocks

Columns

Authors

Topics

No results found

LatestNews





Stock: Teva Pharmaceutical Industries (TEVA) #sankyo #pharma #inc

#barr pharma

#

Teva Pharmaceutical Industries (TEVA)

This article refers to the pharmaceutical company. For the Brazial real (BRL), see Brazilian Real (BRL) .

Barr Pharmaceuticals (formerly BRL) was the parent company for Barr Laboratories and Duramed Pharmaceuticals, Inc. before being acquired by Teva Pharmaceutical Industries (TEVA). Through its two subsidiaries the company produces roughly 75 different generic pharmaceuticals and 19 brand name pharmaceutical products, largely focused on women’s health and birth control.

On July 18th 2008, generic drug manufacturer Teva Pharmaceutical Industries (TEVA) announced it would buy Barr for $66.50 / share in cash and stock. Under the terms of the deal, each share of Barr common stock will be converted into $39.90 in cash and 0.6272 Teva American depositary receipts. Teva said it expects the deal to close in late 2008. [1]

Barr differentiates itself from the competitors in that it only seeks to formulate hard to reproduce brand name drugs, those with complex formulations or difficult to source materials. This strategy provides it with some measure of protection, by making it more difficult for other generics companies to replicate its products. The company may also benefit from overall growth in the generics market as Medicare and private insurance become increasingly receptive to generics, in the face of rising health care costs.

Contents

Business Financials

Barr makes most of its money from sales of generic products. Its sales of $1.3 billion in 2006 were about 75% from generic products and only 25% proprietary medications. As a subset of these areas, Barr’s most important therapeutic area is contraceptives and birth control. The striking difference between revenue and profits (net earnings) in the graphs could in part be caused by Barr’s increased marketing efforts of proprietary products in 2003-2004. Initial costs for marketing a product are very high, and as the patient base expands, these costs decrease meaning profits can increase.

An interesting strategy Barr employs is filing patent challenges first. If the challenge is successful, the company that filed the challenge receives 180 days of “exclusivity” wherein there is no competition from other generic producers.

Error creating thumbnail

Barr Annual Report [2]

Error creating thumbnail

Barr Annual Report [3]

Key Trends and Forces

*Towards Generic Drugs: The generic market has grown significantly in recent years. The percentage of overall prescriptions filled with generic products grew from 46.5% in 2000 to 57.3% by 2005 [4]. The aging population. rising health care costs, and insurance companies’ attempts to minimize costs could all contribute to a further increase in demand for generic products. Medicare spending could also play a significant role in the continued growth of the generics industry. The program which accounts for approx. 12% of the federal budget has been under pressure to cut costs. If Medicare moves to encourage greater use of generics, it would be a huge win for the industry and companies like BARR.

*Patent Expiration: Because Barr’s main focus is on generic drugs, one of the most important factors in determining its profitability are patent expirations of other companies’ successful medications. Pharmaceutical patents are generally short, and the process for gaining FDA Approval for a generic drug is much less rigorous than for a new medication. Often, generic manufacturers only have to prove that their product is equivalent. They do not have to go through the lengthy and expensive process of clinical trials.

When patents expire, often companies will attempt to reformulate products to maintain the patents. By adding new ingredients or changing the formula slightly, patent life can be extended, or brand domination can be maintained through the new formula. Thus, even if it appears that a patent will expire, there is no guarantee that this will really open up the market for generic manufacturers.

Error creating thumbnail

Barr Annual Report [5]

*Legal Challenges: Part of being a generic manufacturer means dealing with the “edge” of patents. That is, there is likely a gray area between when a product is protected by patent and when it is not. Because of this, companies such as Barr often face law suits from brand manufacturers. Currently, Barr has been fighting over patents on Yasmin, Ortho, Try-Cyclen Lo, and Allegra-D, which seem to be coming to an end soon.

*Brand Loyalty: Because patent laws allow brand name medications to monopolize the market for a certain number of years, brands have a chance to build loyalty and get people “hooked.” For example, if a patient is taking medication for a life-threatening condition, such as heart disease, doctors are unlikely to switch the patient to a new medication.

*Contraceptive Products: The market for contraceptives is especially important to Barr. One of its major products, the “morning after pill” called Plan-B, is very controversial in some areas. The product causes a fertilized egg not to implant itself in the uterus, and many claim that this is essentially a type of “pre-abortion.” Thus, legislation effecting abortion, as well as pharmacists’ ability to refuse to fill prescriptions, will effect sales of Plan-B. Also, there is constantly new research on side effects of oral contraceptives and hormones. If it is found that there are negative effects, Barr’s sales could suffer.

Competition

Because patent expiration means that any company can now access the formula of a medication and manufacture it, competition is fierce. Barr has a unique way of side-stepping some competition. It relies on four “qualifications” in deciding what products to produce. These include:

  1. Those with complex formulation or development characteristics;
  2. Those requiring specialized manufacturing capabilities;
  3. Those where sourcing the raw material may be difficult;
  4. Those that must overcome unusual regulatory or legal challenges, including patent challenges.

These conditions are designed to create generics that other companies cannot easily create. Barr goes after the more difficult products to manufacture, meaning that it will face less competition than if it went after easy products.

Error creating thumbnail

Company Annual Reports [6]

Barr’s major competitors including are:

  • Teva Pharmaceutical Industries (TEVA). Teva Pharmaceuticals USA is one if the largest producers of generic drugs. Its products include therapeutic areas such as anti-infective, cardiovascular, oncology, dermatological and anti-inflammatory.
  • Sandoz, a generic division of Novartis AG (NVS). Sandoz’s major therapeutic areas include antibiotics, preparations for treating the central nervous system, cardiovascular, hormones and antiallergics.
  • Mylan Laboratories (MYL) is the third largest generic producer in the US. Mylan also owns subsidiaries that produce proprietary drugs and hospital packages.
  • Dr. Reddy’s Laboratories (RDY) is one of the largest generic manufactures in the US by revenue. It also manufactures branded products. Dr. Reddy’s products include those for hypertension, allergies, urological disorders, cardiovascular, and antibiotics.

Notes





HZNP Stock Price & News – Horizon Pharma PLC – Wall Street Journal #biotechnology #careers

#horizon pharma

#

Horizon Pharma PLC HZNP (U.S. Nasdaq)

P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock’s most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period. Earnings Per Share (TTM) A company’s net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock’s price. For companies with multiple common share classes, market capitalization includes both classes. Shares Outstanding Number of shares that are currently held by investors, including restricted shares owned by the company’s officers and insiders as well as those held by the public. Public Float The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded. Dividend Yield A company’s dividend expressed as a percentage of its current stock price.

Key Stock Data

P/E Ratio (TTM)
EPS (TTM)
Market Cap
Shares Outstanding
Public Float
Yield

HZNP has not issued dividends in more than 1 year.

Latest Dividend
Ex-Dividend Date

Shares Sold Short The total number of shares of a security that have been sold short and not yet repurchased. Change from Last Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month. Percent of Float Total short positions relative to the number of shares available to trade.

Short Interest (08/15/16)

Shares Sold Short
Change from Last
Percent of Float

Money Flow Uptick/Downtick Ratio Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an “uptick” in price and the value of trades made on a “downtick” in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.

Stock Money Flow

Uptick/Downtick Trade Ratio

Real-time U.S. stock quotes reflect trades reported through Nasdaq only.

International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times.

Quote data, except U.S. stocks, provided by SIX Financial Information.

Data is provided “as is” for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

All of the mutual fund and ETF information contained in this display was supplied by Lipper, A Thomson Reuters Company, subject to the following: Copyright © Thomson Reuters. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Bond quotes are updated in real-time. Source: Tullett Prebon.

Currency quotes are updated in real-time. Source: Tullet Prebon.

Fundamental company data and analyst estimates provided by FactSet. Copyright FactSet Research Systems Inc. All rights reserved.





HZNP Stock Price & News – Horizon Pharma PLC – Wall Street Journal #generic #pharmaceutical

#horizon pharma

#

Horizon Pharma PLC HZNP (U.S. Nasdaq)

P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock’s most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period. Earnings Per Share (TTM) A company’s net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock’s price. For companies with multiple common share classes, market capitalization includes both classes. Shares Outstanding Number of shares that are currently held by investors, including restricted shares owned by the company’s officers and insiders as well as those held by the public. Public Float The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded. Dividend Yield A company’s dividend expressed as a percentage of its current stock price.

Key Stock Data

P/E Ratio (TTM)
EPS (TTM)
Market Cap
Shares Outstanding
Public Float
Yield

HZNP has not issued dividends in more than 1 year.

Latest Dividend
Ex-Dividend Date

Shares Sold Short The total number of shares of a security that have been sold short and not yet repurchased. Change from Last Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month. Percent of Float Total short positions relative to the number of shares available to trade.

Short Interest (08/15/16)

Shares Sold Short
Change from Last
Percent of Float

Money Flow Uptick/Downtick Ratio Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an “uptick” in price and the value of trades made on a “downtick” in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.

Stock Money Flow

Uptick/Downtick Trade Ratio

Real-time U.S. stock quotes reflect trades reported through Nasdaq only.

International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times.

Quote data, except U.S. stocks, provided by SIX Financial Information.

Data is provided “as is” for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

All of the mutual fund and ETF information contained in this display was supplied by Lipper, A Thomson Reuters Company, subject to the following: Copyright © Thomson Reuters. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Bond quotes are updated in real-time. Source: Tullett Prebon.

Currency quotes are updated in real-time. Source: Tullet Prebon.

Fundamental company data and analyst estimates provided by FactSet. Copyright FactSet Research Systems Inc. All rights reserved.





  • 1
  • 2